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SUMMARY 
 
The flaviviruses include several important human pathogens of global medical 
importance. Diseases caused by the dengue viruses, West Nile virus (WNV) and Japanese 
encephalitis virus (JEV) have been classified as emerging diseases and are continuing to 
spread into new territory. The overall objective of this thesis was to address two fundamental 
issues that underlie the biology of flaviviruses: recombination among flavivirus genomes and 
packaging of the viral genome. To this end, an innovative trans-complementation system was 
established in this thesis. This system consists of two genomes each lacking a different part of 
the viral structural protein genes. Thus, neither of these so-called replicons is able to produce 
infectious virions by itself. When introduced together into the same host cell, however, they 
are able to complement each other and both replicons can be packaged into virion particles. 
Thus, these two replicons can be repeatedly passaged together providing ample opportunity 
for recombination events potentially generating full-length, infectious genomes. This system 
was applied to three different flaviviruses, i.e. tick-borne encephalitis virus (TBEV), WNV, 
and JEV  
Surprisingly, in no case the recombination trap produced wild-type genomes by exact, 
homolgous cross-over events different from the general assumption that this would be the 
most likely event to occur. Intermolecular recombination yielding infectious full-length 
viruses was observed for one of the three viral systems, namely JEV. However, rather than 
generating wild-type genomes, aberrant homologous recombination resulted in recombinant 
JE viruses with unnatural gene arrangements and reduced growth properties compared to 
wild-type virus. In spite of the absence of any inter-molecular recombination events, the 
TBEV recombination trap evolved defective genomes with larger deletions presumably by a 
intra-molecular recombination process. The resulting mutants lacked part of a nonstructural 
protein gene and were thus by themselves incompetent for RNA replication. However, in the 
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presence of the other replicon (or an infectious virus) these defects could be complemented in 
trans leading to successful replication of these mutants which thus represent proper sense 
‘defective interfering particles’.  
The fact that all of these deletion mutants could be packaged into virions demonstrated 
that these sequences were not essential for the packaging process. To analyze the 
requirements for packaging within the capsid protein in more detail, the WNV capsid protein 
was subjected to a specific deletion analysis. Artificially introduced deletions into a conserved 
hydrophobic region were mostly well tolerated. Spontaneously emerging pseudorevertants 
surprisingly included two mutants with significantly extended deletions removing more than a 
third of the entire capsid protein. Further analysis confirmed that those minimal capsids 
allowed packaging of the viral genome.  
In summary, this thesis demonstrates that flavivirus genomes have a very low 
propensity, if any, for homologous recombination and provides the first laboratory 
recombination system yielding an aberrant homologous recombination event between 
flavivirus genomes. Furthermore, the data indicate that flavivirus genomes can readily 
undergo intramolecular recombination events leading to extended deletion mutations. The 
spontaneously formed defective interfering particles as well as viable capsid deletion mutants 
provided information on requirements for packaging of the viral genome. 
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ZUSAMMENFASSUNG 
 
Das Genus Flavivirus umfasst eine Reihe wichtiger menschlicher Krankheitserreger. So sind 
zum Beispiel das Dengue, West Nile oder Japanische Enzephalitis Virus als 
wiederaufkommende Erreger klassifiziert worden und dringen in neue Gebiete vor. Das Ziel 
dieser Doktorarbeit war, zwei wichtigen Aspekten der Biologie von Flaviviren auf den Grund 
zu gehen: einerseits die Rekombination von Flaviviren und andererseits die Verpackung des 
viralen RNA Genoms. Hierfür wurde ein neuer, innovativer Ansatz entwickelt. Das 
Grundprinzip beinhaltet zwei defekte Viren, so genannte Replikons, denen jeweils 
unterschiedliche Viruspartikelbausteine fehlen wodurch sie keine infektiösen Viruspartikel 
mehr bilden können. Beide Replikons besitzen jedoch die Fähigkeit in einer Wirtszelle das 
virale Genom zu vervielfältigen und in Proteine zu übersetzen. Wenn beide Viren in der 
gleichen Zelle vorhanden sind, kodieren sie für alle Proteine, die für ein Viruspartikel nötig 
sind. Tatsächlich konnten wir zeigen, dass beide Replikons in infektiöse Partikel verpackt 
werden. Allerdings ist das System nicht so effizient wie ein einzelnes Genom auf dem alle 
Virusbausteine kodiert sind. Aus diesem Grund können „Ganzlängengenome“, die durch 
Rekombination der beiden defekten Genome entstehen können, in Zellpassagen gesucht 
werden. Dieses System wurde auf die drei Flaviviren Frühsommermeningoenzephalitis Virus 
(FSME), WNV und JEV angewandt. 
Interessanterweise, wurde in keinem Fall exakte homolge Rekombination zu Wildtype Virus 
beobachtet, obwohl dies als sehr wahrscheinlich galt. Allerdings konnte Rekombination zu 
infektiösen Ganzlängen Viren in einem der drei Virussystemen gezeigt werden. Beim JE 
Virus führte ungenaue homologe Rekombination zu Viren mit ungewöhnlicher 
Genomstruktur und im Vergleich zum Wildtype Virus reduzierten Wachstum. 
Obwohl keine intermolekulare Rekombination zu infektiösen Viren beim FSME Virus 
gefunden werden konnte, entwickelten sich die defekten FSME Viren durch den Verlust von 
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Sequenzen, herbeigeführt wahrscheinlich durch einen intramolekularen 
Rekombinationsprozess. Den enstandenen Mutanten fehlte ein Teil eines 
Nichtstrukturproteins wodurch sie nicht mehr in der Lage waren ihr RNA Genom zu 
vervielfältigen. Allerdings konnte dieser Defekt in Anwesenheit eines Replikons (oder eines 
infektiösen Virus) kompensiert werden. Die Mutanten erlangten dann wieder die Fähigkeit ihr 
Genom zu vervielfältigen und stellten damit im eigentlichen Sinn defekte hemmende RNA 
Moleküle dar. 
Die Tatsache, dass diese Mutanten in Viruspartikel verpackt werden konnten, zeigte, 
dass die ihnen fehlenden Sequenzen nicht für die Verpackung wichtig waren. Um die 
Anforderungen an das Kapsidprotein für die Verpackung genauer zu analysieren, wurde das 
Kapsidprotein des WNV genauer untersucht. Die Wegnahme von kurzen Sequenzen in einer 
konservierten, hydrophoben Region wurde vom Virus zwar toleriert. In zwei Fällen traten 
jedoch Revertanten auf, denen mehr als ein Drittel der Sequenz für das WNV Kapsidprotein 
fehlten. Eine genauere Analyse zeigte, dass diese reduzierten Kapside ausreichten um das 
virale Genom zu verpacken.  
Zusammenfassend zeigt diese Dissertation, dass Flaviviren eine sehr geringe Tendenz 
zu homologer Rekombination aufweisen. Zugleich beschreibt sie das erste 
Rekombinationssystem im Labor, das ein ungenaues Rekombinationsereignis zwischen 
Flavivirus Genomen zeigen konnte. Darüber hinaus deuten die Ergebnisse darauf hin, dass 
Flaviviren eher zu intramolekularer Rekombination neigen, was zum Verlust von Sequenzen 
führt. Die spontan enstandenene defekten hemmenden RNA Moleküle sowie die 
funktionstüchtigen WNV Kapsid Mutanten lieferten Informationen über die Verpackung des 
viralen Genoms. 
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INTRODUCTION 
 
1. Genus Flavivirus, Family Flaviviridae 
 
The family Flaviviridae consists of three genera: Pestivirus, Hepacivirus and Flavivirus. The 
Genus Flavivirus is the largest genus comprising over 70 viruses, many of which are 
important human pathogens. Although, some flaviviruses have no known vector, most 
members are either transmitted by mosquitoes or ticks which also constitutes two different 
genetic lineages. Further, the members of the genus Flavivirus can be grouped serologically 
into different groups (figure 1). 
 
 
Figure 1. Flavivirus classification. Flaviviruses can be grouped into different groups 
according to serological (serocomplex), phylogenetical (clades) or transmitting vector 
(cluster) (106). 
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 1.1. Epidemiology and disease 
 
1.1.1. Japanese encephalitis virus (JEV) 
 
JEV is the most important cause of viral encephalitis in eastern and southern Asia, with 
30,000-50,000 cases reported annually. Most infections are asymptomatic but 25-30% of the 
reported cases result in fatal disease and 50% in neurological sequelae (93). Clinical disease 
varies from non-specific febrile illness to meningoencephalitis, aseptic meningitis or polio-
like acute flaccid paralysis (137). JEV is transmitted in a zoonotic cycle between mosquitoes 
and pigs and/or water birds. Humans become infected only coincidentally and are dead end 
host. There exist two licensed vaccines, the Chinese SA14-14-2 strain, which due to 
international safety requirements cannot be used outside of China and a Vero cell produced 
formalin inactivated SA-14-14-2 strain by Intercell (IXIARO®) which has just been licensed 
for use in Europe and the US. 
1.1.2. West Nile virus (WNV) 
 
Two distinct lineages have been defined for WNV: Lineage 1 includes the NY-99 strain that 
was responsible for the introduction of WNV to the US and Kunjin which represents an 
attenuated subtype circulating in Australia. Lineage 2 includes several African strains but all 
reported cases of severe illness were caused by strains of lineage 1 (117). The transmission 
cycle of WNV is maintained in a bird-mosquito-bird cycle and humans are only incidental 
hosts (93). When humans become infected, in most cases WNV causes a mild febrile illness 
or the infection remains asymptomatic. However, in 1 out of 150 infections a severe and 
sometimes fatal encephalitis, meningoencephalitis or hepatitis have been reported, especially 
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in elder patients (118). Although, a number of different WNV vaccines are at the stage of 
clinical trials (18)(47) at the moment exists only a veterinary vaccine that has been 
successfully used in horses (18). 
 
1.1.3. Tick-borne encephalitis virus (TBEV) 
 
Three subtypes of TBEV have been phylogenetically defined: European, Far Easthern and 
Siberian (31). In Western Europe the principal vector for TBEV is Ixodes ricinus while in 
Eurasia it is Ixodes persulcatus. Typically, TBEV is transmitted in a zoonotic cycle between 
ticks and small vertebrate hosts, mainly rodents, although larger animals like birds or deer can 
get infected as well. Occasionally, the direct transmission to humans drinking unpasteurized 
milk from infected goat, sheep or cow has been reported (122). Approximately 70% of TBEV 
infections are asymptomatic, the remaining percentage can develop an febrile illness after an 
incubation period of 3 to 7 days after the tick bit. Symptoms include fever, headache, malaise 
and nausea. After an asymptomatic phase that may last from 1 to 33 days, in about one third 
of the patients, fever returns accompanied with symptoms affecting the central nervous 
system, such as meningits or meningogoencephalitis. A small percentage of patients sustain 
long-lasting or permanent neurological sequelae. The case fatality rate is below 1% with 
infections of the Western subtype but can be as high as 40% with the Far Easthern subtype. In 
Austria about 90% of the population is vaccinated with a formalin inactivated whole virus 
vaccine which originally has been developed with major input from scientists of  the Institute 
of Virology in Vienna. 
 
 
1.2. Molecular Organization of Flaviviruses 
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1.2.1. Genome organization and virus particle 
 
 
Flaviviruses are positive-stranded RNA viruses. The 11kb-long genome contains a cap 
structure at its 5’ end but no poly-A tail at its 3’ end. It encodes only a single open reading 
frame which is translated into a polyprotein. Posttranslational cleavages by viral and host 
proteases yield three structural proteins: the membrane (M), envelope (E) and capsid (C) 
proteins, as well as seven non-structural proteins that are essential for viral replication (figure 
2)(90) (89).  
 
 
Figure 2. Shematical drawing of a Flavivirus full-length genome. C, capsid; M, membrane; E. 
envelope; NCR, non-coding region. 
 
For example, NS5 is the viral RNA-dependent RNA polymerase (RdRp) and NS-3 is a 
multifunctional protein containing a serine protease domain at its N-terminus necessary for 
the processing of the viral polyprotein and helicase domain at its C-terminus which is part of 
the viral replication complex. Non-coding regions that are rich in RNA secondary structure 
are located at both ends of the genome. These structures have been associated with diverse 
functions controlling replication and translation of the RNA genome (97). Flavivirus virions 
are composed of a single copy of the positive-stranded RNA genome that is packaged by the 
capsid protein C into a nucleocapsid. The nucleocapsid is engulfed by a lipid envelope 
containing the surface glycoproteins prM and E (figure 3).  
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Figure 3. Schematic drawing of 
a mature Flavivirus virion. The 
nucleocapsid which lacks a 
defined form is surrounded by a 
host derived lipid bylayer in 
which the surface glycoproteins 
M and E are inserted (140). 
 
1.2.2. Flavivirus life cycle 
 
1.2.3. Entry and Genome replication 
 
Flaviviruses attach to the surface of a host cell by a yet unidentified receptor.  An involvement 
of heparin sulfate (HS) during attachment and entry has been suggested but its availability on 
the host is not essential for virus uptake (95). Although, no specific cellular receptor has been 
identified, it was established that Flaviviruses enter the cell by receptor mediated endocytosis 
via clathrin coated pits (24). After endocytosis, viral particles are found in uncoated 
prelysosomal vesicles, where fusion of viral and host membrane occurs (89). The RNA 
genome is released into the cytoplasma where replication takes place at the perinuclear 
membrane in virus induced vesicular packets. First, the plus-strand of the viral genome directs 
the synthesis of the viral polyprotein in association with the host membrane (figure 4). Once 
the viral polymerase and other essential proteins are synthesized, the viral RNA is copied. 
RNA replication of the viral genome starts with the synthesis of a negative-strand RNA from 
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which new viral genomic RNA is produced. The process of replication is asymmetric, leading 
to a 10- to 100-fold excess of positive-strands over negative strands (25). 
 
 
Figure 4. Flavivirus life cycle (140). 
 
1.2.4. Assembly and Egress 
 
The glycoproteins prM and E drive budding at the membrane of the endoplasmic reticulum 
(ER)(106). Subviral particles devoid of a nucleocapsid are routinely observed as a by-product 
of flavivirus infections (3) and can be produced by recombinant expression of the two viral 
surface proteins prM and E alone (2). However, preformed nucleocapsids are usually not 
observed in flavivirus-infected cells, indicating that virion formation is a coordinated process 
between the membrane-associated capsid protein and prM-E heterodimers in the ER. After 
intracellular budding at the endoplasmic reticulum immature particles are transported through 
the trans-Golgi network, followed by the cleavage of prM by the host protease furin. Mature 
virions and subviral particles are subsequently released from the host cell by exocytosis (139). 
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1.2.5. Flavivirus packaging and the capsid protein 
 
For many viruses, specific elements on the packaged genome (such as the psi signal on 
retrovirus genomes) or specific protein determinants have been identified which ensure the 
specificity and efficiency of this crucial process. Although it is clear that flaviviruses also 
package their genome with high specificity and efficiency, the determinants that underlie this 
process are essentially unknown. On the RNA level, it has been speculated that specific RNA 
elements present in the terminal non-coding regions may function as packaging signals (97), 
but there is no experimental evidence for this hypothesis. Some studies suggest that packaging 
is tightly coupled to and dependent on RNA replication (70). Other studies indicate that non-
structural proteins may also be involved in this process (83).  
On the protein level, positively charged regions of protein C appear to be involved in RNA 
binding, but no specificity has been demonstrated for this binding (72). Further it is believed 
that a hydrophobic sequence element which is present at a conserved position in all flavivirus 
capsid protein sequences (figure 5) plays an important role in packaging. The functional 
importance of this conserved internal hydrophobic domain has been demonstrated by studies 
with a variety of flaviviruses. For example, characterization of TBEV capsid deletion mutants 
showed that the proportion of infectious virions to non-infectious capsidless subviral particles 
shifted towards subviral particles with increasing deletion length (77). In addition large 
deletions were tolerated only upon the acquisition of additional mutations increasing the 
hydrophobicity of the protein (80). Further, studies on YFV protein C (115) and WNV(131), 
showed that removal of the entire helix α2, which includes the conserved domain produced a 
noninfectious phenotype. In DENV, removing large parts of this hydrophobic domain 
abolished the ability to dimerize in vitro(149) which is a prerequisite for the formation of the 
nucleocapsid and the ability to associate with the ER membrane (98). Taken together, these 
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studies underlined the important role of the conserved internal hydrophobic sequences in 
virion assembly. 
 
Figure 5: Multiple sequence alignment of flavivirus capsid proteins. Residues with high 
similarity (>50%) are red, and the conserved residues highlighted. The secondary structure is 
indicated at the top. The conserved hydrophobic region of flaviviruses is shaded gray. KUN, 
Kunjin; MVE, Murray Valley encephalitis; SLE, St. Louis encephalitis; YFV, yellow fever; 
LIV, loupin ill; LAN, Langat; POW, Powassan virus.(92) 
 
2. RNA Recombination  
 
The versatility of RNA viruses depends on divers and rapid genetic changes. Error-prone viral 
polymerases can cause single nucleotide substitutions at high rates and allow them to quickly 
adapt to new environmental challenges (62). In addition, it has become increasingly clear that 
many RNA viruses add the capacity to exchange genetic material with one another to their 
evolutionary repertoire. RNA recombination has been observed in all types of viruses using 
RNA as a carrier of genetic information: in positive-sense, single-stranded RNA viruses 
((84)), in negative-sense, single-stranded RNA viruses ((142)), in double-stranded RNA 
viruses ((113)) and in retroviruses ((156)). Moreover, it has been shown that RNA 
recombination enables the exchange of genetic material not only between the same or similar 
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viruses but also between distinctly different viruses ((153)). There are also examples in which 
host derived sequences have been identified in viral RNAs: For example a sequence from 28S 
rRNA inserted in the hemagglutinin gene of an influenza virus (67) and a tRNA sequence in 
Sindbis virus RNA (105) or an ubiquitin-coding sequence in bovine viral diarrhea virus (99). 
  
2.1. Mechanism of RNA recombination: Replicase driven template switch 
 
DNA recombination progresses according to a breakage and joining mechanism, involving 
hetero-duplex formation of the two recombining molecules (Holliday junction). In contrast, 
the most accepted model for RNA recombination is a replicase-driven template switch 
mechanism. Here, recombinants are formed during the replication when the viral polymerases 
jumps or switches from one RNA template (donor RNA) to another (acceptor RNA). The 
strongest evidence in favor for this mechanism is provided by the work of Kirkegaard and 
Baltimore on homologous recombination in poliovirus (74). In this study, after super-infection 
of wild-type virus (guanidine sensitive and temperature resistant) with a double mutant 
(guanidine resistant and temperature sensitive) the production of progeny resistant to 
guanidine and temperature was monitored. Interestingly, co-infection in two consecutive steps 
resulted in the inhibition of the replication of the first virus and yielded more than 100 fold 
difference in the yield of recombinants depending on which restrictive factor was applied at 
super-infection. Specifically, the number of recombinants was high when the cells were 
super-infected with the wild-type virus at an elevated temperature and low when the cells 
were super-infected with the mutant virus in the presence of guanidine. Accordingly, such an 
asymmetric result could not be produced by a breaking and joining mechanism inasmuch as 
the parental genomes were equally abundant in each case but because of the asymmetric 
influence of restriction factors on RNA synthesis. Moreover, a later study showed that the 
frequency of recombination events increased throughout the replication cycle of the virus 
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(61). The dependency of recombination on RNA replication for homologous recombination 
has further been confirmed in a RNA recombination system for brome mosaic bromovirus 
where mutations within the two virus-encoded components of the replicase influenced the 
frequency of recombinants (107) (110). Another piece of evidence came from the study of 
aberrant homologous recombination of Turnip crinkle virus, which detected non-templated 
nucleotides at the site of cross-over. This finding further supports the hypothesis that 
recombination simultaneously takes place with replication (17). Even though, this model 
represents the most accepted mechanism, it is still unclear if it is operative in all RNA viruses. 
For example, studies on Brome mosaic virus showed that mutations in the viral polymerase 
selectively decreased only non-homologous recombination but did not affect the frequency of 
homologous recombination (35). Therefore, an additional mechanism has been proposed for 
RNA recombination. The generation of a recombinant sequence can also be conceived via 
breaking the parental sequences and joining the resulting fragments. The first evidence of a 
nonreplicative transesterification mechanism was obtained in the in vitro Qß phage system 
which employed Qß phage replicase to detect replicable RNA species generated from 
nonreplicable RNA fragments (23). Interestingly, these studies revealed that non-homologous 
recombination occurred in the absence of replication while homologous recombination was 
observed in a control experiment, in which the same RNA fragments were incubated in the 
presence of dNTPs and a reverse transcriptase (112). However, the presence of Qß replicase 
required for amplification of the recombinant molecules did not fully exclude a replicative 
mechanism. Further reports of non-replicative recombination exist for picornavirus between 
overlapping 5’ and 3’ RNA fragments of the poliovirus genome (45) but in this study the 3’ 
fragment contained the complete RdRp and therefore it could not be excluded that minimal 
levels of translation led to expression of the viral polymerase promoting recombination via a 
replicative template switch mechanism. In the genus Pestivirus of the family Flaviviridae, 
transfection of overlapping 5’ and 3’ fragments of the bovine viral diarrhea virus, each 
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lacking different essential parts of the viral RdRp gene yielded recombinant full-length 
genomes demonstrating at last the existence of a viral polymerase independent mechanism for 
RNA recombination (38). However, the exact mechanism remains to be elucidated. 
 
2.2. Types of RNA recombination 
 
Initially, RNA recombination has been typed as homologous and non-homologous. However, 
this definition was adapted from DNA recombination and can not easily be applied to RNA 
recombination. Due to the mechanism of template switching sequence pairing seems less 
important for facilitating recombination between RNA than between DNA molecules. Other 
factors such as RNA secondary structures (see below) have been described to redirect the re-
initiation point of the viral replicase. This means that even though homologous sequences are 
present on donor and acceptor strand the point of cross-over may not be determined by 
sequence matches. Therefore, examination of recombination end products can be misleading, 
however according to current theories including the structure of intermediates and the 
recombination machinery the following three types of recombination have been proposed 
(84)(110). 
 
2.2.1. Type I Homologous recombination or similarity essential recombination. 
Homologous recombination occurs if substantial 
sequence similarity on donor and acceptor strand is 
provided and part of this sequence is the major 
determinant of the recombination event which 
directs the cross-over to a region of identical 
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sequence. The created RNA molecules retain the exact sequence and structural organization 
of the parental RNAs. Most of RNA recombination involving full-length viral genomes, such 
as recombination of picornaviruses, is of this type. 
 
2.2.2. Type II Aberrant homologous or similarity-assisted recombination 
 
Similar to type I recombination, there is homology between the parental RNAs of type II 
recombination. The difference is that cross-over does not occur at homologous or compatible 
sites. This imprecise template switch often leads to sequence alterations (insertion, duplication 
or deletions) at the site of cross-over. In addition, to sequence similarity, other factors such as 
RNA secondary structures can influence both the frequency and position of recombination. 
This type of recombination is unique to RNA recombination. It is particularly common, when 
defective RNAs are involved in recombination. 
                                              (110) 
 
2.2.3. Type III Non-Homologous or similarity non essential recombination 
 
Type III recombination includes events between two RNA molecules that either share no 
sequence homology or there is no apparent requirement for sequence similarity or identity. 
Type III recombination would therefore be independent of base-pairing and other factors such 
as polymerase binding sequences or hetero-duplex formation between parental RNAs may be 
involved in re-initiation of the replicase. The frequency of non-homologous recombination is 
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rarely reported. One explanation for this is that many recombination systems involve selection 
of viable or replication competent recombinant genomes. Non-homologous recombination 
often changes the genome structure which increases the probability of non-viable 
recombinants. Therefore, possible non-homologous recombinants exhibit growth deficiencies 
and need to further evolve to gain fitness to become detectable. Such additional adaptation 
often involves deletion of redundant sequences which can lead to recombinant viruses with a 
wild-type like genome organization which would indicate a homologous recombination event. 
                                             (110) 
 
2.3. Factors favoring RNA recombination 
 
2.3.1. Available data on animal viruses 
 
In general, examination of cross-over points suggests that RNA recombination is a chance 
event and thus each nucleotide in an RNA molecule may serve as target for recombination 
(133). It has been suggested that a combination of structure and/or sequence on the donor 
strand that serves momentarily to slow the elongation rate of the viral polymerase can provide 
the kinetic window allowing the switch between templates(61). In accordance with this 
hypothesis, studies of recombinant inter-typic RNA virus genomes of poliovirus revealed that 
all identified cross-over sites were flanked by or located within RNA secondary structures and 
a continuous identical sequence in the cross-over region of minimal 5 nucleotides was 
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observed in the described homologous recombinant genomes (144)(123). Similarly, a study 
on mouse hepatitis virus reported the possible involvement of RNA secondary structure in 
recombination of coronaviruses (5). Interestingly, the frequency of homologous 
recombination decreased when the degree of sequence homology between co-infecting 
polioviruses molecules was reduced (74) (144). To gain more knowledge of the mechanism of 
RNA recombination, in-vitro recombination systems have been created and even though no 
consensus sequence has been identified to be essential for RNA recombination, a wide 
spectrum of RNA motifs supporting recombination or increasing its frequency have been 
characterized. For example, bovine viral diarrhea virus polymerase NS5B (family 
Flaviviridae, genus Pestivirus) was shown to be able to produce RNAs longer than template 
length in vitro, because of the enzyme switching template either at the 5’ end or within the 
template RNA (73). Analysis of template sequence and RNA secondary structure revealed 
that the sequence within 7 nucleotides from the 5’terminus of the template (or donor) RNA 
could affect the frequency of recombination. While a high propensity for recombination with 
G-C rich base pairing near the site of cross-over was observed, no simple correlation between 
the recombination frequency and the number of hydrogen bonds between the template and the 
nascent transcript was observed, indicating the existence of other contributing factors. In 
addition, comparative analysis with other viral polymerases indicated that the 
structure/function of the replicase also greatly affects the frequency of template switch (73). 
 
2.3.2. Lessons from plant viruses 
 
2.3.2.1. Brome mosaic bromovirus (BMV) 
 
Brome mosaic bormovirus genomes consists of three separate RNA molecules designated 
RNA1, RNA2 and RNA3. RNA1 and RNA2 encode BMV replicase proteins 1a and 2a, 
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respectively. RNA3 encodes movement and coat proteins. Recombinantly active mutants of 
RNA3 can be constructed by insertion of artificial sequences. Non-homologous 
recombination or recombinants with imprecise cross-over were observed after insertion of 66 
nts in RNA 3 which were complementary to a respective region on RNA 1. Insertion of the 
corresponding region in direct orientation did not give detectable RNA1/3 recombinants 
(109). Further studies with this system revealed that longer heteroduplexed regions supported 
recombination at higher frequency than shorter ones. Also, shorter than 30 nt heteroduplexed 
regions did not induce RNA1/3 recombinants at detectable level (107). Analysis of 
homologous recombinants generated between RNA2/3 defined that 15 or longer sequence 
identity between RNA2 and RNA3 can support efficient, while 5 and 9nt long common 
regions supported only reduced levels of homologous recombination. No recombinants were 
detected when the common region was 4 or none. Introduction of mismatch mutations 
reduced the number of recombinants and at the same time caused a shift in the location of 
cross-overs towards the non-mutagenized portion (107). Further, AU-rich sequences were 
frequently detected at crossover regions and were shown to support high frequency 
recombination (108). In addition, the presence of GC rich sequences was shown to function as 
recombination enhancers (110). These observations indicated that homologous recombination 
is different from non-homologous recombination with respect to sequence/structure 
requirements. While hetero-duplex formation and strong RNA secondary structures favored 
non-homologous recombination, local sequence homology and AU-rich sequences played a 
major role in homologous recombination of brome mosaic bromovirus.  
 
2.3.2.2. Turnip crinkle virus (TCV) 
 
In contrast to the bromovirus family, the genome of Turnip crinkle carmovirus (TCV) is 
composed of a single positive-sense RNA of 4kb. The virus genome is frequently associated 
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with a number of subviral RNAs, including satellite, defective-interfering and chimeric RNAs 
(111). RNA species of the latter two groups were shown to be the products of natural 
recombination (17). In vivo examination of recombination between common sat RNA D and 
sat RNA C suggested the involvement of a hairpin structure (motif1-hairpin) on the acceptor 
RNA (=sat RNA C) for high frequency of recombination between these two RNAs. In-vitro 
studies of this process helped to develop a model which suggested that the motif1-hairpin is 
involved in recruitment of the RdRp during re-initiation of synthesis following template 
switch. In addition, a short base-paired region formed between the acceptor RNA and the 
nascent RNA was shown to influence the frequency of recombination (111). This suggested 
that according to a template switch mechanism, the viral RdRp can dissociate with the nascent 
transcript and then re-initiation at the motif1-hairpin is assisted by the base-paired region and 
3’ terminal extension is facilitated. These studies confirm the assumption that both RNA 
secondary structures and local sequence pairing play a role in mediating RNA recombination. 
 
2.3.3. Involvement of host genes 
 
Beside the obvious involvement of the viral proteins of the replication complex (107) (61) 
(35) in RNA recombination, several host genes were shown to influence both the occurrence 
and frequency of RNA recombination (132) (21). Analysis of the effect of a single-gene 
deletion library of Saccharomyces cerevisiae on recombination of a positive strand RNA virus 
(Family Tombusviridae) led to the identification of four host genes inducing recombination 
and five other genes inhibiting it. The genes able to suppress RNA recombination were shown 
to be involved in the RNA metabolism/degradation (table 1). Based on the known function of 
genes able to increase the frequency of recombination, the authors suggested that either a 
change in intracellular transport of viral and/or host proteins (or possibly protein-viral RNA 
complexes) to the site of recombination (PEP7 and DC11), and/or differences in the lipid 
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content/structure of the membranous compartment (IPK1, CH02, and DCI1), which contains 
the virus replicase, influences RNA recombination efficiency.  
 
Table.1. Names and functions of host genes affecting RNA recombination 
Gene Molecular function/biological process 
 Supressors 
CTL1 Polynucleotide 5’-phosphatase 
MET22/HAL2 3’(2’),5’Bisphosphate nuleotidase 
HUR1 unknown 
XRN1 5’-3’ exoribonuclease 
UBP3 Ubiquitin-specific protease 
 Accelerators 
PEP7/VPS19 Unknown/Golgi to vacuole transport 
IPK1 Inositol/phosphatidylinositol kinase 
CHO2/PEM1 Phsophatidylethanolamine N-
methyltransferase 
DCI1 Dodecenoyl-CoA Δ-isomerase 
 
2.4. Generation of defective interfering RNA (DI RNA) 
 
Not all RNA viruses have been shown to be able to undergo intermolecular RNA 
recombination (i.e. Vesicular stomatitis virus, West Nile virus, Tick-borne encephalitis virus, 
Newcastle disease virus and RNA phages). However, nearly all RNA viruses generate 
recombinant subgenomic deletion particles designated defective interfering particles (DI 
particles). These RNA genomes retain all cis-acting regulatory sequences required for 
replication and packaging of the RNA, but their replication depends on enzymes and 
structural proteins provided by infectious helper virus.  Notably, their replication interferes 
with closely related viruses able to act as helpers (121). DI RNAs are most efficiently 
generated under conditions in which many infectious virus genomes simultaneously infect the 
same cell (55). It has been suggested that DI RNAs arose by intermolecular recombination 
according to the copy choice model (17)(116)(87) (King, A.M.Q. 1988. Genetic 
recombination in positive strand RNA viruses, p150-185. In E. domingo, J.J. Holland, and P. 
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Ahlquist (ed.), RNA genetics II. CRC Press, Inc., Boca Raton Fla.). One obvious example is 
the generation of DI RNA of Sindbis virus, in which tRNA sequences are incorporated at the 
5’ terminus of the virion RNA (146). Some satellite RNAs of TCV (discussed above) also 
contain nonviral sequences of unknown origin (17). Further, structural analysis of a DI RNA 
of influenza virus supports the hypothesis of intermolecular recombination for its generation 
(34). The analyzed RNA has been shown to consist of several discontinuous regions, some of 
which were derived from RNA-1 and others from RNA-3. Thus, it may represent a true 
recombinant RNA between two different RNA molecules, although both RNAs belong to the 
same virus. Moreover, it was shown that coronavirus recombination occurred more frequently 
within a hypervariable region (5), in which deletions commonly occur after virus passage in 
tissue culture or animals. Thus, the same RNA secondary structure, i.e. strong stem-loop 
structures, may be responsible for both deletions (intramolecular) and recombination 
(intermolecular) by causing a pause in RNA transcription. In conclusion, the generation of DI 
RNA, the occurrence of deletions, insertions or duplication as well as true recombination of 
viral genomes may all be linked to the model of template switch, in which the viral 
polymerase jumps either within or between the same (intramolecular) or between different 
(intermolecular) templates of replication. 
 
2.5. The extent of recombination in the family Flaviviridae 
 
2.5.1. Genus Flavivirus 
 
Most phylogenetic evidence indicates that evolution of Flaviviruses is clonal, with diversity 
generated largely by the accumulation of point mutations rather than recombination events 
(46). However, some sequence-based phylogenetic studies have suggested the occurrence of 
homologous recombination among strains of the same viral species. Several recent 
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publications have identified recombinant Flaviviruses by computational sequence analysis of 
viral isolates from infected patients. These studies suggested that homologous recombination 
had occurred between closely related virus strains of all four dengue virus serotypes 
(57)(143)(1), JEV  (147) and St. Louis encephalitis virus (147). However, there is a complete 
lack of direct experimental evidence for Flavivirus recombination occurring in, for example, 
double-infected cells or animals.  
The controversy over whether or not Flavivirus genomes can recombine carries significant 
practical importance. A commentary by Seligman and Gould published in the Lancet (130) 
warned against the use of live Flavivirus vaccines because of the danger of creating new 
chimeric viruses with unpredictable biological properties if recombination occurs with other 
Flaviviruses that circulate in the environment and accidentally infect vaccinees. This report 
caused a stir among scientists and health officials because live Flavivirus vaccines (e.g. 
against YFV) are an invaluable and much-needed tool to combat life-threatening diseases 
(103). Several studies have provided at least indirect evidence that the propensity of 
Flavivirus RNA to undergo homologous recombination is low or nonexistent. Recombination 
events were not observed in any trans-complementation packaging studies in which 
replication competent defective virus genomes can be packaged by in-trans expressed 
structural proteins. These systems include expression plasmids, cell lines that have been 
modified to constitutively express Flavivirus structural proteins and alphavirus-based 
expression systems. However, since recombination may depend on Flavivirus RNA 
replication, the fact that the structural proteins in these systems were expressed either from 
cellular mRNAs or alphavirus-derived mRNAs, could mean that the necessary conditions for 
recombination were not provided in these experiments. In another study, replication-deficient 
Flavivirus genomes carrying disabling mutations in one of the non-structural proteins were 
successfully complemented by replicating helper RNA, leading to the production of single-
round-infectious particles (68). Although recombination was not observed under these 
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conditions either, the experimental design of this study probably would not have allowed low-
frequency events to be detected. No experimental studies with the purpose of achieving inter-
species recombination have been described so far.  
On the other hand, several studies have shown that Flavivirus genomes can spontaneously 
acquire deletion or sequence-duplication mutations (33)(80). Such mutations are thought to 
occur by a mechanism in which the RNA polymerase falls off from the template and re-
initiates synthesis at a site further upstream or downstream. A similar event is assumed to 
occur during recombination of RNA, when the polymerase dissociates from the first template 
and then continues synthesis from a different template (see above Generation of DI RNA). 
The observation that spontaneous deletions and duplications readily occur provides indirect 
evidence that the Flavivirus replication complex is capable of undergoing processes of the 
kind that can lead to recombination.  
 
2.5.2. Genus Pestivirus 
 
In the case of pestiviruses, such as bovine viral diarrhea virus, heterologous RNA 
recombination is frequently observed in nature and is responsible for changes in viral 
pathogenicity (99, 100). RNA recombination was first observed in connection with the 
molecular characterization of cytopathogenic (cp) BVDV strains that are involved in the 
induction of lethal mucosal disease in cattle (14). Further studies of cp pestiviruses revealed 
that most cp strains evolved from persisting non-cp viruses by recombination (100). As a 
result, cp pestiviral genomes harbor genomic alterations that frequently include insertions of 
cellular mRNA or viral sequences as well as deletions or duplications of viral sequences (10, 
12)(99, 100). In cell culture passages such cp strains were shown to loose the phenotype 
altering sequences by reverting to non-cp viruses  (11)(7). Both homologous and non-
homologous recombination mechanisms - the latter being more frequent - have been 
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described in this context.  Surprisingly, under laboratory conditions, recombination has been 
demonstrated with BVDV even with non-replicating defective virus genomes suggesting a 
polymerase independent recombination mechanism (for comparison, see the above chapter on 
“Mechanism of RNA recombination”) (38). 
 
2.5.3. Genus Hepacivirus 
 
The genus Hepacivirus consists of only one established species Hepatitis C virus (43) , which 
is classified into six genotypes and several additional subtypes. Similarly to the genus 
Flavivirus, recombination in the genus Hepacivirus has been demonstrated only indirectly by 
phylogenetic analysis of different isolates. By such means, intra-genotypic (27)(26) as well as 
inter-genotypic (63) homologous recombinant viruses were identified. Despite these findings 
and the frequent co-detection of multiple genotypes in patients (64)(59)(29) the available data 
suggests that RNA recombination plays only a minor role in the evolution of HCV. In one 
study, only one out of 89 analyzed sequences turned out to be a recombinant virus (27). In 
another study, monitoring of HCV co-infected patients failed to detect recombinant viruses, 
even though some patients were infected with the same subtype (13).   
 
2.6. Recombination in other positive stranded RNA virus families 
 
2.6.1. Picornaviruses 
 
The family Picornaviridae comprises several important pathogens, such as poliovirus or foot-
and–mouth-disease virus. Poliovirus is the best studied virus regarding RNA recombination. It 
has been shown to exhibit the highest rate of homologous recombination (10-5/nt or 1% for 
every 1700nts) (22), but non-homologous recombination was suggested to be almost equally 
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efficient (82). Frequent detection of recombinant viruses after vaccination with polio vaccine 
strain raised the issue of the stability and safety of the vaccine (16)(101). Generally, 
recombination occurred more readily between more closely related picornaviruses and was 
shown to decrease as the genetic relationship diverged. However, this may only reflect the 
greater probability of viable recombinant genomes between closely related viruses rather than 
the influence of homologous sequences on the actual recombination frequency. 
 
2.6.2. Coronaviruses 
 
Coronaviruses contain a positive-sense RNA genome that is unusually large (31kb), which is 
almost twice the size of the next largest viral RNA (paramyxovirus). The discovery of RNA 
recombination of murine hepatitis coronavirus (MHV) was the first proof that also other RNA 
viruses than picornaviruses are capable of this mechanism (85). Studies indicated that similar 
to picornaviruses, coronaviruses can recombine at high frequency because the isolated 
recombinant viruses showed evidence of multiple cross-overs, sometimes even outside of the 
selection markers (66)(65)(94). The estimated rate of recombination was as high as for 
picornaviruses (10-5/nt or 1% for every 1700nts) (88). Recombination mapping of cross-over 
sites of MHV revealed that the recombination frequency was higher near the 3’ end, 
indicating a possible involvement of subgenomic mRNAs in recombination (36, 37).  So far, 
only homologous recombination has been detected between coronaviruses. The absence of 
non-homologous recombination in coronaviruses may reflect their rigid viral RNA or protein 
structure requirements for optimal viral growth.  
 
2.6.3. Alphaviruses 
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In contrast to picorna- and coronaviruses, homologous recombination in alphaviruses seems 
to be uncommon concerning data obtained from recombination studies under laboratory 
conditions (150)(51). Only one study also identified homologous recombinants in the lab 
(120). Intriguingly, a homologous recombinant virus was discovered in nature. 
Recombination between Eastern equine encephalitis virus and a virus related to Sindbis virus 
resulted in the lineage of Western equine encephalitis virus (50). Interestingly, one of the 
putative crossover sites in WEEV RNA was located in the middle of the structural protein-
coding region, such that the structural proteins of WEEV have two different origins, with the 
capsid protein gene being derived from EEV and the rest of the structural proteins being 
derived from Sindbis virus.  
 
2.7. Recombination in negative stranded RNA virus families 
 
Little is known about the recombination mechanism of negative stranded RNA viruses 
because the available data was almost exclusively obtained by phylogenetic analysis of 
isolated genome sequences. Recombinant viruses have been reported in arenavirus (4) and 
(20), hantavirus (75), (136), influenza A virus (44), measles virus (126), and Newcastle 
disease virus (HN gene) (19). Generally, negative-sense RNA viruses have lower rates of 
recombination than positive-sense RNA viruses (119). This assumption is supported by a 
single report of RNA recombination under experimental conditions for a nonsegmented 
negative strand RNA virus (respiratory syncytial virus) (138). In a classical co-infection 
experiment with different marker mutations and consecutive plaque purification only one 
recombinant virus was detected. The genome of the recombinant virus was generated by 
double cross-over between the parental viruses involving non-homologous as well as 
homologous recombination events (138). 
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2.8. Recombination of Retroviruses 
 
The fact that retrovirus particles contain two copies of the RNA genome and that transcription 
makes use of both RNAs results in an extraordinary high propensity for recombination 
(141)(58). Estimates for the recombination rate of HIV in vivo are as high as 1.4x10-4 
recombination events / site / generation, which is about fivefold greater than the average point 
mutation rate (134). Recombination is believed to occur during the reverse transcription 
process according to the template switch mechanism of the copy-choice model. Intriguingly, 
recombination predominantly occurs between co-packaged RNA genomes and co-infection 
with two different viruses does not yield a high number of recombinants. This suggests that 
each particle provides its own reverse transcriptase and the copied RNA genomes are not 
freely exchanged with other RT-reactions in the cytoplasm of the same cell. This 
compartmentalization of the replication location is also observed for many other RNA viruses 
replicating in the cytoplasm. In this context it is important to note that host genes involved in 
the induction or maintenance of membranous structures were shown to influence the 
frequency of recombination. In conclusion, the physical separation of RNA genomes from 
different virus particles within a cell may pose a critical constraint on the occurrence of 
recombination of other “haploid” RNA viruses replicating in the cytoplasm. 
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AIMS 
 
This thesis addresses two fundamental issues that underlie the biology of flaviviruses: 
Recombination among flavivirus genomes and determinants of flavivirus genome packaging. 
These two main objectives can be subdivided into four individual goals. 
 
Goal 1: Establishement of a reciprocal trans-complementation system  
The reciprocal trans-complementation system will involve two different replicons, each 
lacking part of the structural protein coding region, which is, however, present in the other 
one, will be simultaneously introduced into the same host cell. Together, the two replicons 
will express all of the structural components necessary for particle formation. Replication of 
both replicons in the same cell will lead to the expression of all of the components necessary 
for particle production. This will allow to study whether the replicons can be packaged and 
released in the form of single-round-infectious virus like particles (VLPs). Transfer onto fresh 
cells of supernatants containing sufficient concentrations of VLPs to allow double infections 
of cells with VLPs containing both replicons may again lead to VLP production, and these 
passages will be repeated as many times as desired.  
 
Goal 2: Assessment of the propensity for intermolecular recombination 
Replication of two complementary replicons may lead to recombination between the two 
complementing genomes, yielding a full-length infectious virus genome. In contrast to the 
replicon-containing VLPs, the recombined infectious virion will not depend on double 
infections of cells for its propagation and can thus be enriched by subsequent cell culture 
passages. After several limiting dilution passages, it is anticipated that a recombined virus will 
have completely outgrown the two parental replicons and can be characterized by standard 
techniques (Northern blot, PCR, sequence analysis). Complementing replicons of three 
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different flaviviruses, TBEV, JEV and WNV will be tested in this “recombination trap”. If 
recombination to infectious viruses is observed, the recombined genomes will be tested for 
infectivity and growth properties will be assessed in vector and host cells.  
 
Goal 3: Study of other mechanisms involved in adaptation of flaviviruses 
If no recombination to infectious viruses is observed, the defective viruses involved in the 
reciprocal trans-packaging system will be analyzed and tested for adaptive mutations. Such 
mutations may include point mutations, deletions or generation of defective interfering RNAs. 
Analysis of these mutations on the efficiency of the reciprocal packaging will allow new 
insights into flavivirus packaging. Further, it will be interesting to observe whether the 
defective viruses show a greater propensity for intermolecular recombination to infectious 
viruses than for intramolecular changes. 
 
 
Goal 4: Analysis of capsid in flavivirus packaging. An internal hydrophobic sequence 
within the flaviviral capsid protein was shown to play an important role in the assembly of 
infectious TBEV and YFV virions. To systematically test the functional role of hydrophobic 
residues and to define common features of the flavivirus capsid various deletions ranging 
from 4 to 14 amino acids will be introduced into the capsid protein of WNV. Resuscitating 
mutations will be selected in cell culture passages and will allow insights into the basic 
requirements of the nucleocapsid for flavivirus packaging. 
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Abstract 
 
Intermolecular recombination between the genomes of closely related RNA viruses 
can result in the emergence of novel strains with altered pathogenic potential and antigenicity. 
Although recombination between flavivirus genomes has never been demonstrated 
experimentally, the potential risk of generating undesirable recombinants has nevertheless 
been a matter of concern and controversy with respect to the development of live flavivirus 
vaccines. As an experimental system for investigating the ability of flavivirus genomes to 
recombine, we developed a "recombination trap", which was designed to allow the products 
of rare recombination events to be selected and amplified. To do this, we established 
reciprocal packaging systems consisting of pairs of self-replicating subgenomic RNAs 
(replicons) derived from tick-borne encephalitis virus (TBEV), West Nile virus (WNV), and 
Japanese encephalitis virus (JEV) that, due to different deletions in the region encoding their 
structural proteins, individually lacked the ability to produce infectious virions but could 
complement each other in trans and thus be propagated together in cell culture over multiple 
passages. Any infectious viruses with intact, full-length genomes that were generated by 
recombination of the two replicons would be selected and enriched by endpoint-dilution 
passage, as was demonstrated in a spiking experiment. Using the recombination trap, we 
detected two aberrant recombination events using the JEV system, both of which yielded 
unnatural genomes containing duplications. Infectious clones of both of these genomes 
yielded viruses with impaired growth properties. Despite the fact that the replicon pairs shared 
approximately 600 nucleotides of identical sequence where a precise homologous crossover 
event would have yielded a wild-type genome, this was not observed in any of these systems, 
and the TBEV and WNV systems did not yield any viable recombinant genomes at all. Our 
results show that intergenomic recombination can occur with flaviviruses but that its 
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frequency appears to be very low and therefore probably does not represent a major risk in the 
use of live attenuated flavivirus vaccines. 
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Author Summary 
 
Effective live vaccines against the flaviviruses yellow fever virus and Japanese 
encephalitis virus have been in use for decades, and tetravalent live vaccines against dengue 
viruses are currently undergoing clinical testing. Recently, concerns that flavivirus strains 
might have the potential to exchange genetic information by recombination – and generate 
new strains with undesirable properties – have led some researchers to question the safety of 
using live flavivirus vaccines. In the present study, we have developed a "recombination 
trap", a sensitive experimental system for studying flavivirus recombination. This system 
consists of a pair of defective viral genomes, so-called replicons, that are mutually dependent 
because each provides the other with an essential protein required for making virus particles. 
The replicons are propagated together in cell culture for multiple generations under conditions 
that favor the positive selection of any viable virus particles that might arise due to 
recombination. Surprisingly, we observed not a single homologous recombination event using 
recombination traps designed for three different flaviviruses, tick-borne encephalitis virus, 
West Nile virus, and Japanese encephalitis virus (JEV). With JEV, however, we twice 
observed the generation of a recombinant virus with an unnatural genome organization that 
had arisen through a more random process known as aberrant homologous recombination. 
These viruses were impaired in their growth properties. This is the first time that 
recombination of flavivirus genomes has been observed in the laboratory. Our data suggest 
that homologous recombination occurs infrequently, if at all, with flaviviruses and therefore 
probably does not represent a major risk when using live flavivirus vaccines. 
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Introduction 
 
RNA viruses are able to undergo rapid genetic changes in order to adapt to new hosts 
or environments. Although much of this flexibility is due to the error-prone nature of the 
RNA-dependent RNA polymerase, which generates an array of different point mutations 
within the viral population (62), recombination is also a common and important mechanism 
for generating viral diversity (55, 84, 110, 153). Recombination occurs when the RNA-
dependent RNA polymerase switches templates during replication -- an event that is favored 
when both templates share identical or very similar sequences. Three types of RNA 
recombination have been identified: homologous recombination occurs at sites with exact 
sequence matches; aberrant homologous recombination requires sequence homology, but 
crossover occurs either upstream or downstream of the site of homology, resulting in a 
duplication or deletion; and non-homologous (or illegitimate) recombination is independent of 
sequence homology (84, 110).  
When the same cell is infected by viruses of two different strains, or even different 
species, recombination between their genomic RNAs can potentially lead to the emergence of 
new pathogens. A case in point is the emergence of western equine encephalitis virus (WEE), 
a member of the genus Alphavirus, family Togaviridae, which arose by homologous 
recombination between eastern equine encephalitis virus and Sindbis virus (50). 
Some mammalian RNA viruses can recombine at a frequency that is detectable in 
experimental settings (6, 8, 150), and phylogenetic analysis of partial or complete genome 
sequences suggests that RNA recombination is a widespread phenomenon. Naturally 
occurring recombinant viruses have been identified in almost every family of positive-
stranded RNA viruses (84, 153).  
RNA recombination is increasingly being recognized as an important parameter to 
consider in the development of vaccines containing live attenuated viruses (153). Experience 
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with live poliovirus vaccines has already shown that new strains can indeed arise in vaccinees 
due to recombination  between vaccine strains, and possibly between vaccine strains and other 
viruses (16, 28). The potential hazards of homologous recombination events involving live 
vaccine strains has become a concern and an obstacle to the development of flavivirus 
vaccines. Flaviviruses are members of the genus Flavivirus, family Flaviviridae, a family 
which also includes the genera Pestivirus and Hepacivirus. Several of the flaviviruses are 
important human pathogens, such as Japanese encephalitis virus (JEV), West Nile virus 
(WNV), the dengue viruses, yellow fever virus, and tick-borne encephalitis virus (TBEV).   
Live vaccines for the prevention of some flaviviral diseases are already in widespread 
use. Vaccines containing the live yellow fever virus strain 17D, one of the first viral vaccine 
strains ever developed, have been in continuous use since the 1950s, with over 500,000 
administered doses per year (124). A live vaccine against JEV containing the attenuated strain 
SA-14-14-2 has been widely used in China since 1988 and also shows an excellent safety 
record so far (91). 
Although there has never been a report of a pathogenic flavivirus strain arising due to 
recombination involving attenuated vaccine strains (103), the urgent necessity to develop 
tetravalent vaccines containing all four serotypes of dengue virus – two such vaccines are 
currently undergoing clinical testing (125) -- has recently brought the recombination issue to 
the forefront of discussion among researchers, regulators, and vaccine producers (103). It has 
been suggested that recombination, either between the strains present in a multivalent vaccine 
or between an attenuated vaccine strain and a wild-type strain, could lead to the emergence of 
new viruses with unpredictable properties (130). 
So far, recombination between flavivirus genomes has not been demonstrated directly 
in the laboratory. However, phylogenetic analysis of partial genome sequences available in 
the GenBank database has suggested that homologous recombination may have occurred 
between closely related strains of dengue virus (57, 143, 148, 154), JEV (147),  and St. Louis 
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encephalitis virus (147).  An experimental approach for assessing the ability of flavivirus 
genomes to recombine is therefore urgently needed. 
Flavivirus virions are composed of a single-stranded, positive-sense RNA genome that 
is packaged by the capsid protein C into a nucleocapsid. The nucleocapsid is covered by a 
lipid envelope containing the surface glycoproteins prM and E. These glycoproteins drive 
budding at the membrane of the endoplasmic reticulum (ER) during the assembly stage and 
mediate entry of the virus into host cells (106). Replicons, defined as self-replicating, non-
infectious RNA molecules, can be generated by deleting parts or all of the region coding for 
the structural proteins C, prM, and E from the viral genome but maintaining all seven of the  
nonstructural proteins and the flanking noncoding sequences, which are required in cis for 
RNA replication (76). By providing the missing structural protein components in trans, 
replicons can be packaged into virus-like particles that are capable of a single round of 
infection (41, 52, 71, 128). 
Typically, researchers developing novel replicating vaccines, especially ones that 
involve multiple components, make an effort to come up with strategies to prevent 
recombination, for example by "wobbling" codons, i.e., replacing codons in homologous 
regions with synonymous ones encoding the same amino acid but consisting of a different 
nucleotide triplet (135, 152). In this study, in order to assess the propensity of flavivirus 
genomes to recombine, we took an opposite approach, establishing a "recombination trap" 
that favors the selection and sensitive detection of recombination products. This system takes 
advantage of the ability of replicon pairs containing deletions in their structural protein genes 
to complement each other in trans and thus be propagated together in cell culture, and by 
passage at limiting dilution, it allows infectious RNA genomes arising by recombination 
between the two replicons to be preferentially selected.  
Using the recombination trap, we have now obtained the first direct evidence of 
recombination between flavivirus genomes in the laboratory. Aberrant homologous 
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recombination was observed twice with JEV replicons, resulting in viruses with unnatural 
gene arrangements and reduced growth properties compared to wild-type JEV. No infectious 
recombinants of any kind were obtained when TBEV or WNV replicons were used. 
Interestingly, we never detected a fully infectious wild-type genome arising by homologous 
recombination in any of these systems. The results of this study show that the propensity of 
flavivirus genomes to recombine appears to be quite low and suggest that recombination does 
not represent a major risk in the use of live attenuated flavivirus vaccines. 
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Results 
 
Establishment of a reciprocal packaging system 
As a tool for testing the propensity of flaviviruses for recombination, we established a 
reciprocal packaging system to allow the co-cultivation of two different defective viruses for 
prolonged passages. This system consisted of two replicons, each of which contained a 
deletion in a region of the RNA genome that encodes structural proteins that are essential for 
virus assembly. Individually, each of these replicons was incapable of forming infectious 
virus particles due to the lack of an essential component for virion assembly, but when present 
together in the cytoplasm of the same cell, they were capable of complementing each other in 
trans, thus allowing each of the defective genomes to be packaged and propagated as single-
round infectious (or pseudoinfectious) particles and allowing co-passage of these replicons in 
cell culture. By conducting passages at limiting dilution, functional revertant wild-type virus 
genomes resulting from recombination between the two replicons could potentially be 
selected and enriched. 
To set up the two-component trans-complementation system, we took advantage of 
two previously described and characterized TBEV replicons called ∆C (78) and ∆ME-eGFP 
(42). As shown in Fig. 1, replicon ΔC consisted of a full-length TBEV genome containing a 
186-bp deletion in the region encoding the capsid (C) protein, and ∆ME-eGFP lacked the 
entire region encoding the envelope proteins prM and E. In addition, ∆ME-eGFP contained an 
additional artificial cistron inserted in the 3' noncoding region (3' NCR) that allowed the 
expression of the enhanced green fluorescent protein (eGFP) under the control of an IRES 
element. 
To test the ability of these replicons to complement each other and to be packaged into 
infectious particles, BHK-21 cells were first transfected with each of the in vitro-synthesized, 
capped replicon RNAs, either individually or in combination. Transfected cells containing 
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replicon ∆C were identified using an immunofluorescence assay with a monoclonal antibody 
recognizing the envelope protein E, which was expressed in ∆C but not in ∆ME-eGFP. Using 
a rhodamine-conjugated secondary antibody for detection, the cells containing ∆C RNA 
appeared red under the fluorescence microscope (Fig. 2, left), as did control cells infected 
with the full-length wild-type (WT) genomic RNA, which also expressed the E protein. 
Transfected cells containing replicon ∆ME-eGFP appeared green under the fluorescence 
microscope. 
When BHK-21 cells were transfected by electroporation with an equal mixture of the 
two replicons (Fig. 2, bottom left), it was observed one day after transfection that some cells 
were positive for eGFP (green cells), some for E (red cells), and some for both (yellow cells 
in the merged image), indicating that they contained both ∆C and ∆ME-eGFP. 
Supernatants from each of the transfected cell cultures were then applied to fresh 
BHK-21 cells, and the cells were tested 24 h later for the presence of E and eGFP (Fig. 2, 
right). After one passage, the cells treated with the supernatant from the cotransfected culture 
(∆C+∆ME-eGFP) again showed a mixed pattern of green, red, and yellow cells, indicating 
that each of the replicons had been packaged into infectious particles and that a subset of the 
cells had been coinfected with both replicons. As expected, the supernatants from cells 
transfected with defective ∆C or ∆ME-eGFP RNA alone apparently did not produce 
infectious particles, and these replicons could not be propagated further. Also as expected, the 
supernatants from the positive control cells that had been transfected with full-length 
infectious genomic RNA (WT) were able to infect fresh cells, as indicated by positive red 
staining for the viral E protein (Fig. 2, top right). 
In this passage experiment, the presence of cells containing both ∆C and ∆ME-eGFP 
suggested that the frequency of coinfection was high enough to enable a further round of 
trans-complementation and packaging of replicon RNAs. To test this, the supernatants from 
passage 1 were again transferred to fresh cells, and, as shown in Fig. 2 (bottom right, "Passage 
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2"), a similar pattern was observed, with cells containing ∆C, ∆ME-eGFP, or both. These 
experiments demonstrate that replicons ∆C and ∆ME-eGFP, when used together, constitute a 
reciprocal packaging system that can be propagated in cell culture by serial passage. 
 
Analysis of individual foci 
Next, we infected fresh BHK-21 cells with various dilutions of supernatants 
containing the mixture of packaged ∆C and ∆ME-eGFP replicons, added a methylcellulose 
overlay, and fixed and stained the cells 50 hours later using an anti-TBEV polyclonal 
antibody and an alkaline-phophatase-conjugated secondary antibody to detect the formation 
of infectious foci. As shown in Fig. 3A, the mixture of packaged replicons formed foci that 
were smaller than those formed by wild-type TBE virus, demonstrating that the ability of 
infectious material to spread from replicon-containing cells was impaired compared to that of 
the virus control. Furthermore, unlike wild-type virus, which showed a linearly proportional 
decrease in the number of plaques formed with increasing dilution, the number of foci formed 
with the packaged replicon mixture decreased very sharply with increasing dilution (data not 
shown). This sensitivity to dilution is consistent with what would be expected if two particles, 
one containing ∆C and the other containing ∆ME-eGFP, were required to make one infectious 
unit (i.e., one focus-forming unit). 
To examine the foci more closely, cells were again infected with different dilutions of 
the ∆C and ∆ME-eGFP mixure and overlaid with nitrocellulose as above, but instead of 
staining with polyclonal serum and alkaline phosphatase, the cells were fixed and prepared for 
detection of E and eGFP by fluorescence microscopy as described in the previous section. An 
example of a typical focus formed by infection with a mixture of packaged ∆C and ∆ME-
eGFP replicons at high dilution is shown in Fig. 3B. In the merged images, each of these foci 
could be seen to consist of a mixed population of cells, some of which were green (∆ME-
eGFP), some red (∆C), and some yellow (∆C + ∆ME-eGFP), similar to what was observed 
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earlier in confluent monolayers shown in Fig. 2. This means that each of the foci was formed 
by infection of neighboring cells by particles containing ∆C or ∆ME-eGFP RNA, or by both 
types of particles simultaneously. Importantly, examination of more than 100 individual foci 
in this manner did not reveal any that consisted of only red-stained E-protein-producing cells, 
which would have been expected if a wild-type revertant virus had arisen in the population 
due to recombination between the replicons. 
 
Competition between replicons and full-length viral genomes 
In contrast to the defective replicon-containing particles, a fully infectious virion 
carrying a full-length genome would not depend on multiple infection of the same cell for its 
propagation, and if it were present in the population, it could be enriched by subsequent cell 
culture passages at high dilution. To test this principle experimentally, we carried out an 
experiment similar to the ones described above, except this time we spiked the mixture of 
packaged replicons with 10 focus-forming units (ffu) of wild-type TBE virus to see whether 
the full-length genome would eventually become dominant after serial passage at limiting 
dilution. For this experiment, however, instead of ∆ME-eGFP, we used a replicon called ∆ME 
(41), which was identical to ∆ME-eGFP except that it had a normal viral 3' end and lacked the 
artificial cistron encoding eGFP (Fig. 1). Lysates of infected BHK-21 cells were analyzed 
after the initial infection and after three endpoint-dilution passages by northern blotting using 
a probe recognizing the nonstructural region of the genome. As shown in Fig. 4A, the 
replicons were initially detected after infection, but after the three passages, only a single 
band was observed, corresponding in size to the full-length genome. The presence of the wild-
type virus genome replacing the two replicons was confirmed by a set of RT-PCRs (Fig. 4B) 
and sequencing (not shown). RT-PCR 1 was specific for the wild-type sequence, whereas RT-
PCRs 2 and 3 yielded specific bands for replicons ∆C and ∆ME, respectively, as well as a 
larger band for the wild-type RNA. After three passages, only the products specific for the 
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wild-type sequence were obtained by all three RT-PCR assays (Fig. 4B). This experiment thus 
showed that the full-length viral genome had displaced the replicons during passage in cell 
culture and demonstrates that this system can be used as a "recombination trap" for selecting 
potential wild-type revertants within the population of replicating RNAs. 
 
Application of the recombination trap 
 The replicon constructs used in the previous set of experiments for establishing the 
reciprocal packaging system, although identical in the region encoding the nonstructural 
genes, contained only a small stretch of 27 identical nucleotides between the C and prM genes 
where a single homologous recombination event could result in the creation of a full-length 
genome by restoring the missing capsid gene in ∆C (Fig. 1). Therefore, in order to increase 
the likelihood of such an event, we constructed a new replicon to use in place of ∆ME that 
increased the region of identical sequence between the deleted regions. This construct, called 
∆E, had all of the E gene deleted (nt 973-2460) but retained the entire prM gene as a 572-nt 
region of common sequence identity where homologous recombination with ∆C could 
potentially take place (Fig. 1). In addition to the TBEV constructs, we also made analogous 
∆C and ∆E replicons using genomic clones of the mosquito-borne flaviviruses West Nile 
virus (WNV) and Japanese encephalitis virus (JEV) (Fig. 1).  
 The recombination trap was then put to use by cotransfecting BHK-21 cells with the 
TBEV, WNV, and JEV ∆C and ∆E replicon pairs and carrying out multiple endpoint-dilution 
passages to favor the selection and enrichment of any viruses with full-length genomes that 
might arise by recombination. Full-length infectious clones of each virus were used as 
controls. After 10 endpoint passages, intracellular RNA was analyzed by gel electrophoresis 
and northern blotting with virus-specific probes (Fig. 5A). As expected, each of the full-
length, wild-type controls yielded a single major band. In the case of TBEV, transfection with 
∆C together with ∆ME or ∆E resulted in two major bands (Fig. 5A, left panel, lanes 3 and 4) 
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that corresponded in size to the original replicons (lanes 5, 6 and 7), suggesting that the two 
original replicons had been co-passaged and maintained throughtout the entire 10 passages.  
Likewise, cotransfection of ∆C and ∆E from WNV also yielded both replicon bands (Fig. 5A, 
middle panel, lane 3).  
In contrast to these results, however, in the case of JEV, northern blotting revealed 
only a single band after passage of the ∆C+∆E pair, suggesting that the replicons were not 
propagated as a pair and that a recombination event might have occurred. This phenomenon 
was observed in two completely separate experiments. Northern blot analysis of earlier 
passages indicated that replacement of the original pair of replicons with the new band had 
already occurred in the third and fifth passage, respectively (data not shown). The relative 
positions of the bands in the gel suggested that the final RNA recombination products were 
not identical in size in the two experiments (Fig. 5A, right panel, lanes 3 and 4).  
As a more sensitive and precise means of assessing whether recombinant RNA 
molecules were present in the population, we devised RT-PCR assays for detecting the 
restoration of deleted regions of the TBEV, WNV, and JEV genomes (see Materials and 
Methods). In these assays, neither of the original replicons could be amplified due to the lack 
of one of the primer-binding sites, but recombinants containing both of these sites would yield 
a PCR product. As shown in Fig. 5B, in the case of TBEV and WNV (left and middle panels, 
respectively), the RT-PCR assay yielded a product in the case of the WT control, but not with 
the passaged replicon pairs, indicating that no detectable reversion to wild-type TBEV or 
WNV had occurred via inter-replicon recombination. With JEV, however, a clearly different 
situation was observed (Fig. 5B, right panel). Positive RT-PCR results were obtained not only 
with the WT control (lane 1) but also with the combination of ∆C and ∆E in the two separate 
experiments (lanes 3 and 4). The first of these PCR products (lane 3) appeared to be larger 
than the one obtained using the wild-type genome, whereas the second (lane 4) was 
approximately the same size. These results provided positive evidence that recombination 
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events had indeed occurred with the JEV system. Other RT-PCR assays that were designed to 
detect the original replicons (see Materials and Methods) failed to yield detectable 
amplification products from the passaged JEV samples, indicating that both replicons had 
been completely displaced by the new recombinant in both of these experiments  (data not 
shown).  
These newly selected recombinant genomes were then reverse-transcribed and 
sequenced. Both of them were found to contain all of the components of the JEV genome, but 
neither corresponded in its arrangement to a wild-type genome. Recombinant 1 (Fig. 6A, top), 
which was obtained in experiment 1, was composed of replicon ∆E sequence from its 5' end 
up to nt 2761 and still included the original deletion of nt 978 to 2477 in the E gene. The 
remainder of the genome was derived from replicon ∆C and included the entire region 
extending from the beginning of prM to the 3' terminus, thereby resulting in an aberrant 
genome containing a partial duplication of the NS1 region and a complete duplication of the 
prM region between prM and E. Recombinant 2 (from experiment 2) resembled the wild-type 
JEV except that it contained a tandem duplication of nucleotides 393-455, corresponding to 
the NS2B/3 protease cleavage site between C and prM (Fig. 6A, bottom). 
 
Growth properties of JEV recombinants 
 To characterize their biological properties, infectious clones of the recombinant 1 and 
recombinant 2 genomes were made as described in Materials and Methods. Full-length RNA 
was synthesized from these templates and used to transfect BHK-21 cells, which in turn 
released infectious particles into the cell supernatant. These viruses were then characterized 
by testing them in a standard plaque assay using Vero cells and by carrying out a multistep 
growth curve experiment using both BHK-21 cells and the mosquito cell line C6/36. 
 The plaque morphology produced by these viruses in Vero cells is shown in Fig. 6B. It 
was observed that the recombinant 1 virus produced large plaques that looked similar to those 
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produced by wild-type JEV. The recombinant 2 virus, on the other hand, produced small 
plaques, suggesting that this virus was impaired in its ability to spread to other cells. 
 The growth curves shown in Fig. 6C, performed using an MOI of 0.01, show that both 
recombinants had impaired growth properties compared to wild-type JEV. Recombinant 2 
grew extremely poorly in BHK-21 cells, whereas the growth rate of recombinant 1 was only 
moderately reduced compared to wild-type JEV. However, the titer of recombinant 1 fell 
sharply after two days due to a strong cytopathic effect (CPE). In C6/36 cells, both of the 
recombinants grew about an order of magnitude more slowly than the wild type, and 
recombinant 1 did not produce an unusually strong CPE in these cells. 
 These results suggest that although passage at limiting dilution apparently gave the 
two aberrant full-length recombinant forms of JEV a growth advantage over the original 
replicon pair, their growth properties would not have allowed them to prevail over a wild-type 
virus, had one been present in the population. We therefore conclude that although aberrant 
recombination events did occur in the JEV system, a normal wild-type revertant was not 
produced by a simple homologous crossover in any of the experiments with JEV, WNV, or 
TBEV. 
 
Discussion 
 
Using a “recombination trap”, an experimental system designed to detect even rare 
recombination events between two self-replicating RNA molecules, we analyzed the 
propensity for intermolecular recombination of three flaviviruses, TBEV, WNV, and JEV. 
The inclusion of long overlapping regions between the two trans-complementing replicons in 
our recombination trap provided ample opportunity for homologous crossover events to 
generate recombinants with wild-type genomes. Surprisingly, however, no such event was 
detected in any of the three flaviviral systems, even after prolonged co-passaging, indicating 
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that exact homologous recombination occurs rarely, if at all, with these viruses. However, we 
did detect two aberrant recombination events in the JEV system, each of which gave rise to 
infectious virus progeny with an unnatural genome organization and an impaired growth 
phenotype.  
The potential for unwanted recombination has been a topic of considerable 
controversy in the context of live flavivirus vaccine and vector development. Until now, the 
only evidence for flavivirus recombination has been inferred from sequence data from certain 
natural isolates (56, 57, 143, 147, 148). However, there has been a lack of general agreement 
about the significance of these observations, and due to the lack of appropriate experimental 
systems, it has not yet been verified under laboratory conditions that flavivirus genomes 
actually recombine. The recombination trap described here provides for the first time a 
sensitive system to address this issue experimentally, and the results obtained using this 
system represent the first direct observation of recombination between replicating flavivirus-
derived RNA molecules in the laboratory. From this study, we can draw three major 
conclusions that are relevant for flavivirus vaccine and vector development:  
(i) Homologous recombination among flavivirus genomes, if it occurs at all, is a very 
rare event. The sensitivity of the recombination trap was demonstrated by the spiking 
experiment, which showed that as little as 10 infectious units of wild-type virus resulted in the 
complete displacement of the two replicons by the infectious wild-type virus within three 
passages. It is reasonable to assume that a single recombination event that gives rise to an 
infectious genome would produce at least 10 infectious particles and would thus outgrow the 
parental replicons within three passages or less. Flavivirus replicons typically multiply to 104 
copies per cell (79, 129), and because the experimental conditions used allowed multiple 
rounds of infection at each passage, we estimate that at least 104 cells per passage would have 
been co-infected with complementary replicons, providing approximately 108 molecules that 
could potentially participate in a recombination event. Thus, a homologous crossover event 
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resulting in the generation of wild-type virus – which could have happened at any position 
within the extended stretch of overlapping sequence identity between the two replicons – 
would  have been selected at a frequency as low as one in 108 per passage. However, the 
generation of wild-type virus was never observed for any of the three flaviviruses although 
they were tested over 10 passages.  
(ii) Aberrant recombination apparently does occur, at least for certain flaviviruses. Despite the 
fact that extensive overlaps of identical sequence were present in our replicon pairs to favor 
crossover events at homologous positions to regenerate wild-type genomes, the only 
recombination events observed were aberrant ones that generated unnatural, rearranged forms 
of the JEV genome. As with homologous recombination, longer sequence overlaps between 
the recombination partners provide more potential non-identical crossover sites and would 
thus be expected not only to increase the likelihood of aberrant recombination within the 
overlap region but also the statistical chances of such an event producing a viable genome. 
Our results also raise the question whether ‘wobbling’ the codons of the overlap region, as has 
been used by some researchers to avoid homologous recombination, would actually reduce 
the recombination frequency if it is indeed confirmed that most crossovers are of the aberrant 
type. Furthermore, it remains unclear why no aberrant recombination was observed in the 
TBEV and WNV systems in spite of equivalent experimental conditions and sequence design.  
It is possible that this kind of recombination is favored by yet undefined RNA 
structures that were present in our JEV sequence but not in those of the other two flaviviruses.  
These questions can be addressed in future experiments with the recombination trap. 
(iii) If recombinants arise, they are likely to have an impaired growth phenotype. 
Aberrant recombination, which occurs by a crossover event at non-identical genome 
positions, generates an unnatural genome organization with sequence duplications. In the case 
of the JEV recombinants generated and analyzed in this study, this unnatural genome 
structure apparently caused growth defects, as demonstrated by a reduced-plaque-size 
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phenotype and/or growth kinetics in different host cells. This suggests that under natural 
conditions, progeny virus derived from such aberrant recombination events would, in most 
cases, have little, if any, chance to compete against the parental wild-type virus.  
Overall, these conclusions suggest that recombination may turn out not to be a major 
concern with regard to live flavivirus vaccines and self-replicating flavivirus vectors. Our 
observations are in good agreement with the fact that, in spite of decades of use of live 
flavivirus vaccines and the co-circulation of several flaviviruses in several endemic areas in 
the world, there has not been a single report of a naturally occurring recombinant involving a 
vaccine strain or of recombination between members of different flavivirus species. 
Furthermore, although numerous experiments with chimeric flaviviruses have clearly 
demonstrated that artificially constructed interspecies recombinants can be viable (49, 54, 60, 
102, 104), such recombinants have never been observed to arise under natural conditions. 
The low rate of recombination, even under conditions strongly favoring the selection 
of recombinants, suggest that recombination probably plays, at most, a minor role in the 
biology and evolution of flaviviruses, and this highlights a striking difference between 
flaviviruses and many other RNA viruses (84). Coronaviruses, for example, frequently 
undergo precise homologous recombination (88), and vaccine strains of poliovirus (a 
picornavirus) have been observed to recombine with each other and with other enteroviruses 
(16, 101). Recombination is also a major driver of genetic diversity and viral evolution of 
retroviruses such as HIV (58, 141), and homologous recombination has also been reported 
among plant RNA viruses. For other viruses, such as alphaviruses and pestiviruses, aberrant 
homologous recombination, and even non-homologous recombination, appear to be more 
common than homologous recombination, but its frequency is still significant (9, 10, 50, 99, 
100, 120). In fact, first-generation packaging systems for alphavirus vectors suffered from the 
risk of frequently observed recombination events between helper and vector replicons, 
regenerating infectious virus (150) – a  problem that has been addressed by the development 
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of tripartite packaging systems and other genetic modifications to prevent successful 
recombination. In the case of the pestiviruses, which belong to the same viral family as the 
flaviviruses, sequences of cellular origin can be acquired by non-homologous recombination, 
driving alterations in viral pathogenicity(10, 12). Homologous recombination in these viruses 
was reduced in a pestivirus study when the sequence identity between recombination partners 
was reduced(39).  
How may the low propensity for recombination between flaviviruses be explained at 
the molecular level? RNA recombination is thought to occur through a process in which the 
RNA replication complex falls off its template and continues RNA synthesis on a different 
template. A similar process is probably involved in the generation of deletion or duplication 
mutations during RNA replication (17, 87). Here, the replication complex also falls off and 
reinitiates, but it does so on the same template molecule upstream or downstream from its 
previous position, thus generating, respectively, duplications and deletions. Spontaneous 
deletion and duplication mutations, in contrast to intermolecular recombination events, are 
frequently observed in flaviviruses (80, 127). If, however, the flavivirus replication complex, 
similar to that of other RNA viruses, is capable of releasing its template and continuing RNA 
synthesis at another location, why would it not be able to freely switch templates in the course 
of this process and thus generate a recombined RNA product? One possible explanation 
would be that replication takes place in individual, secluded compartments within the infected 
cell that predominantly contain RNA derived from a single template molecule (81, 151). An 
alternative explanation would be that the RNA template somehow remains associated with the 
replication complex at a site other than the active site, which would favor re-initiation on the 
same RNA molecule after a temporary release of the template from the active site of the 
synthetase.  
The use of trans-complementation systems such as the ones described here as 
recombination traps will allow more detailed investigation of the types of recombination 
54 
events that flavivirus genomes are capable of undergoing as well as their relative frequencies. 
In addition, the generally low propensity of flavivirus replicons for recombination makes it 
possible for them to be used as reliable tools to study complementation of individual genes 
derived from different viral strains or species. 
 
Materials and Methods 
 
Cells. BHK-21 cells were grown in Eagle’s minimal essential medium (Sigma) 
supplemented with 5% fetal calf serum (FCS), 1% glutamine and 0.5% neomycin (growth 
medium) and maintained in Eagle’s minimal essential medium supplemented with 1% FCS, 
1% glutamine, 0.5% neomycin and 15 mM HEPES, pH 7.4 (maintenance medium). Vero 
cells (ATCC CCL-81) were grown in Eagle’s minimal essential medium supplemented with 
10 % FCS, 30 mM L-glutamine, 100 units of penicillin, and 1 µg/ml streptomycin. Plaque 
assay infections were done in medium containing 1% FCS. Aedes albopictus C6/36 cells were 
grown in Eagle’s minimal essential medium (without NaHCO3) supplemented with 10% FCS, 
20 mM L-glutamine, 100 units of penicillin, 1 µg/ml streptomycin, 13 mM sodium hydroxide, 
19 mM HEPES, pH 7.4, and 0.2 % 50x tryptose-phosphate. For growth curve analysis, the 
FCS concentration was reduced to 1%. 
 
Plasmids and cloning procedures. Plasmid pTNd/c, used for generating infectious 
TBEV, contains a full-length genomic cDNA insert of TBEV strain Neudoerfl (GenBank 
accession number U27495) cloned in plasmid pBR322 (96). RNA transcribed from this 
plasmid was used as the TBEV wild-type virus control. Plasmid pTNd/5’ contains a 5’ cDNA 
fragment of the same viral genome (96). Full-length DNA templates for in vitro transcription 
of TBEV plasmids were generated as described previously (77).  
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pTBEV-ΔC, a derivative of pTNd/c containing a large deletion (62 amino acids) of the 
sequence coding for the capsid protein as well as individual mutations in the signal sequence 
of the capsid protein, was used as the DNA template for in vitro synthesis of replicon ∆C. It 
has been described in an earlier publication (76) in which it was called C (Δ28-89)-S. The 
plasmids for production of replicons ΔME (41) and ΔME-eGFP (42) were also described 
previously. 
Plasmid pTBEV-ΔE, the template for generating TBEV replicon ∆E, was constructed 
by first performing PCR using the primers 5'-ttttaccggtttacgctgatgttggttgcgctgtgga-3' and 5'-
ttccatcgatagtgtgactagcaggccatgagca-3' with pTNd/5' as a template and then cloning this PCR 
product into pTNd/5' using the restriction enzymes AgeI and ClaI. 
For the construction of plasmid pWNV-∆C, the template for generating the WNV ∆C 
replicon, two DNA fragments were made by amplifying portions of the plasmid clone 
pWNV-K1 (127), which contains nucleotides 1-3339 of WNV strain NY99 (isolate Crow 
V76/1). The first fragment was made using the primers 5’-aggtgttccacagggtagcca-3’ and 5’-
ttttggatccttttagcatattgacagccc-3’ and then digesting the resulting product with PacI and 
BamHI. The second fragment was made using primers 5’-tctcggatcctcaaaacaaaagaaaagagg-3’ 
and 5’-aaataggggttccgcgcaca-3’ and digestion with BamHI and NotI. These fragments were 
then mixed with a third fragment generated by digestion of the plasmid pWNV-K4 
(containing nucleotides 3282-11029 from the same WNV strain) with PacI and NotI. Ligation 
of these three fragments resulted in an intermediate construct containing nucleotides 1-3339 
of the WNV genome but lacking nucleotides 151-393 in the C gene, which were replaced by a 
BamHI restriction site. An additional SalI restriction site was created by introducing silent 
nucleotide substitutions at positions 151 and 156  using a site-directed mutagenesis kit 
(Invitrogen) with the primers 5’- gtgtctggagcaacatgggtCgaCttggttctcg-3’ and 5’- 
acccatgttgctccagacactccttccaag-3’ (bold capital letters indicate mutated nucleotides). The full-
length DNA template for RNA synthesis was generated by digestion of pWNV-K1-ΔC and 
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pWNV-K4 with BstEII, followed by in vitro ligation using T4 DNA ligase (Invitrogen) and 
linearization by digestion with NotI. 
For construction of plasmid pWNV-ΔE, pWNV-K1 was used as a template for 
mutagenic PCR using the primers 5’-ttttcacccagtgtcgctgtaagctggggccacca-3’ and 5’-
ttttagatctcgatgtctaagaaaccaggagg-3’. Restriction digestion of the PCR product and WNV-K1 
with BglII and AdeI generated fragments that were ligated to form pWNV-K1-ΔE. This 
partial clone was further digested with PacI and BstEII, and the resulting fragment was cloned 
into pWNV-K4, yielding full-length DNA plasmid pWNV-ΔE. This full-length plasmid was 
linearized by NotI digestion before use as a template for in vitro RNA transcription. 
All constructs containing JEV sequences were based on JEV strain SA-14 (China), 
which was kindly provided by Peter Mason, Yale University. A 5’ clone, pJEV-K3, 
containing nucleotides 1-5616, a 3’clone, pJEV-K4, containing nucleotides 5595-10977, and 
a full-length clone, pJEV/c, containing the whole genome (nt 1-10977) of the wild-type virus 
in pBR322 were generated using standard cloning techniques (manuscript in preparation).  
For construction of pJEV-ΔC, mutagenic PCR was first performed using the primers 
5’-ggcatcgattagtgggaatacgcggggtag-3’ and 5’-aaattaattaatacgactcactatagagaa-3’ with plasmid 
pJEV-K3 as the template. This PCR product and plasmid pJEV-K3 were both digested with 
ClaI and PacI and ligated, forming the intermediate construct pJEV-K3-ΔC. pJEV-K3-ΔC and 
pJEV/c were then digested with PacI and AgeI, and the smaller fragment of pJEV/c was 
replaced by the corresponding fragment of pJEV-K3-ΔC, yielding the full-length cDNA clone 
pJEV-ΔC. 
 For construction of pJEV-ΔE, mutagenic PCR was performed using the primers 5’-
aggcagcccctaggaccagaaccacgttttcttggttcgt-3’ and 5’-
ttttacgcgtggtatttaccatcctcctgctgttggtcgctccggcttacagtgacacttggatgtgccattg-3’ and plasmid 
pJEV-K3 as the template. This PCR product and plasmid pJEV-K3 were both digested with 
AvrII and MluI and ligated together to make the intermediate construct pJEV-K3-ΔE. pJEV-
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K3-ΔE and pJEV/c were then digested with PacI and BamHI, and the smaller fragment of 
pJEV/c was exchanged with the corresponding pJEV-K3-ΔE fragment, yielding the full-
length cDNA clone pJEV-ΔE. 
Infectious clones of JEV recombinants 1 and 2 were made as follows: Cytoplasmic 
RNA that indicated the presence of a full-length virus in the northern blot analysis was 
transcribed into cDNA as described below for RT-PCR. Then, PCR with primers 5’-
tcgagagattagtgcagttt-3’ and 5’-cagtacgacaagtcactatggac-3’ was used to generate a fragment 
that was digested with ClaI and AgeI and exchanged with the corresponding ClaI/AgeI 
fragment of pJEV-K3. Each of these intermediate constructs was cut with AgeI and ligated to 
AgeI-digested pJEV-K4 to form the full-length DNA templates for in vitro transcription. 
 
RNA transfection. In vitro transcription and transfection of BHK-21 cells by 
electroporation were performed as described previously (79, 96, 114). RNA was synthesized 
from full-length cDNA clones or in vitro-ligated full-length templates (see above) using 
reagents of the T7 Megascript kit (Ambion) according to manufacturer’s protocol. The 
template DNA was digested by incubation with DNase I, and the quality of the RNA was 
checked by electrophoresis in a 1% agarose gel containing 6% formalin. RNA was purified 
using an RNeasy Mini kit (Qiagen) and quantified spectrophotometrically. Equimolar 
amounts of RNA were then introduced into BHK-21 cells by electroporation using a Bio-Rad 
Gene Pulser (1.8 kV, 25 µF, 200 Ω). For cotransfections, equal amounts of RNA (~1.1 1012 
copies) of each construct were mixed before electroporation. 
 
Immunofluorescence assays. Twenty-four hours after transfection or infection, BHK-
21 cells were fixed for 20 min with 4% paraformaldehyde in PBS (pH 7.4) and then washed 
two times for 5 min with PBS (pH 7.4) and permeabilized with ice-cold methanol for 6 min at 
-20°C. After three washes with PBS (pH 7.4) and blocking with 3% BSA in PBS (pH 7.4) for 
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30 min at room temperature, intracellular E protein was visualized by sequential incubation 
with a monoclonal mouse antibody against E (1E9) (48) and  a Rhodamine-Red-X-conjugated 
anti-mouse IgG antibody (Jackson Immune Research Laboratory). Simultaneously, eGFP 
fluorescence was enhanced by incubation with a polyclonal rabbit-antibody against GFP 
(Abcam: ab6556), followed by incubation with a fluorescein-isothiocyanate (FITC)-
conjugated anti-rabbit IgG antibody (Jackson Immune Research Laboratory).  
For single-focus immunofluorescence, BHK-21 cells were seeded into 24-well tissue 
culture plates containing microscope coverslips. The confluent monolayer was infected in 
parallel with the dilutions used for the focus assay. Accordingly, cells were treated in the 
same way and covered with a 3% carboxymethyl cellulose overlay dissolved in maintenance 
medium. After 50 hours, cells were washed three times with ice-cold PBS (pH 7.4) and then 
processed for double immunofluorescence staining. Microscopic observation and 
documentation were accomplished by using a LSM 510 scanning confocal microscope (Zeiss) 
and the included software.  
 
Focus assay. Supernatants from BHK-21 cells were collected at passage 1 on day 3 
postinfection. Serial dilutions of supernatants were applied to confluent monolayers of BHK-
21 cells. After a 3-h incubation, supernatants were removed and cells were covered with a 3% 
carboxymethyl cellulose overlay dissolved in maintenance medium. Fifty hours after 
infection, cells were fixed with acetone-methanol (1:1) for 10 min at -20°C and treated with 
polyclonal rabbit anti-TBEV serum. Antibody-labeled cells were detected using an 
immunoenzymatic reaction consisting of sequential incubation with goat anti-rabbit 
immunoglobulin G-alkaline phosphatase and the corresponding enzyme substrate (SigmaFast 
Red TR/Napthol AS-MX tablets). 
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Endpoint passages. Supernatants of infected cells were sequentially diluted, and 200 
µl of each dilution was applied to fresh BHK-21 cells grown in 24-well plates (Nunc). After 
three days, half of the medium was replaced by fresh medium, and after six days, protein E 
released into the supernatant  was detected using a four-layer enzyme-linked immunosorbent 
assay (ELISA) (53) in the case of TBEV and a haemagglutination assay (HA) (127) in the 
case of WNV and JEV. After six days, the highest dilution yielding a positive signal in 
ELISA or HA was cleared of cell debris, sequentially diluted and used for infection of fresh 
BHK-21 cells. 
 
Northern blot analysis. Template DNA for synthesis of RNA probes for northern 
blotting was generated using the following primers and templates: TBEV: template pTNd/c 
and primers agagagcagaagggattga  and tacttaatacgactcactataggtgtgcaagacacccttg generated a 
probe binding to nucleotides 4093-4773 in wild-type virus. WNV: template pWNV-K4 and 
primers agcggctgttggtatggtatg and taatacgactcactataagctgcactcctcttctccct generated a probe 
binding to nucleotides 3448-4107 in wild-type virus. JEV: template pJEV-K4 and primers 
aatggctgctggtacggaatgga and taatacgactcactatacatggtctttttcctctcgtg generated a probe binding 
to nucleotides 3456-4103 in wild-type virus. After phenol-chloroform purification of the 
template DNA, the T7 promoter sequence (underlined) fused to each reverse primer allowed 
RNA synthesis using a T7 MAXIscript In Vitro Transcription Kit (Ambion). The probe RNA 
was labeled by using 0.4 µl of 10 mM Bio-11-UTP (Ambion) instead of UTP. Probe RNA 
was separated from free nucleotides using Micro Bio-Spin 30 columns (BioRad). 
Cytoplasmic RNA was extracted from BHK-21 cells 24 hours after transfection or 
infection. Ten µg of total RNA was applied to a 1% agarose gel, and northern blotting was 
carried out according to the instructions of the NorthernMax-Gly Kit (Ambion). Blotted RNA 
was detected using a BrightStar BioDetect Kit (Ambion). 
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RT-PCR. Reverse transcription-polymerase chain reaction (RT-PCR) was performed 
using the same cytoplamic RNA used for the northern blot analysis, with the primers for 
cDNA synthesis and PCR listed in Table 1. cDNA fragments of the 5’ terminal part of each 
virus genome including the entire sequence coding for the three structural proteins capsid, 
prM and E was synthesized using a reverse primer binding to the sequence coding for NS1 of 
each virus (Table 1). Subsequently, primers binding to sequences absent in both or only one 
of the replicons were used for specific amplification of full-length or replicon cDNA 
fragments of the structural region of TBEV, WNV, or JEV (Table 1). Each PCR was carried 
out using an Advantage® HF2 PCR Kit (Clontech), and amplicons were subjected to 1% 
agarose gel electrophoresis as well as automated sequence analysis as described before (79).   
 
Plaque assays. Vero cells were grown to 80% confluence in 12-well plates and 
incubated for 1 h with virus suspensions serially diluted in maintenance medium. The cells 
were subsequently overlaid with EMEM containing 5% FBS (PAA), 1.5% glutamine (200 
mM, Cambrex), 1% penicillin/streptomycin (10,000 U/ml penicillin, 10 mg/ml streptomycin, 
Sigma), 15 mM HEPES and 0.25% agarose (Sigma). Four days after infection, the cells were 
fixed and stained with a solution containing 4% formaldehyde and 0.1% crystal violet. 
 
Multistep growth curves. Stock preparations of JEV recombinants were generated by 
collecting supernatants of BHK-21 cells transfected with these mutants at day 3 
posttransfection. For analysis of growth properties of recombinant JEV viruses, C6/36 
mosquito cells grown in 6-well plates were infected with wild-type JEV or JEV recombinant 
stock preparations at a low multiplicity of infection (MOI 0.01). Aliquots of supernatants (500 
µl) were taken at different time points, and virus titers were determined by plaque assay. 
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Figure Legends 
 
Figure 1. Structural organization of flavivirus genomes and replicons. Top: Schematic 
drawing of a full-length flavivirus genome. Below: Expanded view of the structural region of 
each replicon. Deletions are indicated by dotted lines, and the missing nucleotides are 
indicated after the "∆" symbol. Nucleotide numbers refer to the position in the corresponding 
wild-type virus sequence. The length of the homologous region that would allow 
recombination to yield a full-length virus is indicated on the right. C, capsid protein; pr, N-
terminal part of prM; M, C-terminal part of prM corresponding to the mature M protein; E, 
protein E; NS, nonstructural protein; NCR, noncoding region; IRES, internal ribosome entry 
site; eGFP, enhanced green fluorescent protein. 
 
Figure 2. Packaging and propagation of complementing TBEV replicons.  Left: Fluorescence 
micrographs showing eGFP and E protein expression in BHK-21 cells 24 hours after 
transfection with in vitro-transcribed full-length genomic RNA or replicon RNA. From top to 
bottom: cells transfected with wild-type RNA, mock-transfected control without RNA, cells 
transfected with ∆C alone, cells transfected with ∆ME-eGFP alone, and cells cotransfected 
with both ∆C and ∆ME-eGFP. Green fluorescence indicates eGFP expression, and red 
fluorescence indicates viral E protein expression. In the merged images shown at the right, 
cells expressing both proteins appear yellow. Right: Cell culture passage 1. Supernatants from 
the transfected cells shown in the left panel were used to inoculate fresh BHK-21 cells, and 
expression of eGFP and E protein was again detected by immunofluorescence staining. 
Bottom: Cell culture passage 2. Supernatants from passage 1 containing both packaged 
replicons were again transferred to fresh BHK-21 cells, and these cells were likewise 
examined by immunofluorescence staining. 
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Figure 3. Analysis of foci. A. Typical foci produced in BHK-21 cells after infection with 
culture supernatants containing wild-type TBEV (left) or a mixture of packaged TBEV 
replicons ΔC and ΔME-eGFP (right). B. Immunofluorescence staining of a single focus 
observed after coinfection with packaged TBEV replicons ΔC and ΔME-eGFP. Cells were 
processed in the same way as for the focus assay shown in A except that instead of an 
immunoenzymatic reaction, immunofluorescence staining was used to detect eGFP and E 
protein expression as in Fig. 2.  
 
Figure 4. Spiking experiment to examine competition between replicons and full-length virus 
genomes. A. Northern blot analysis of total intracellular RNA extracted from BHK-21 cells 
transfected with full-length TBEV genomic RNA (lane 1), TBEV replicon ΔME (lane 2), 
TBEV replicon ΔC (lane 3), or both replicons simultaneously (lane 4). After transfection, 10 
focus-forming units (ffu) of TBEV wild-type virus was added to the supernatant of cells 
cotransfected with replicons ΔME and ΔC, and fresh cells were infected with this mixture. 
Three endpoint passages later, intracellular RNA was examined again, revealing the presence 
of a single RNA species corresponding in size to the viral genome (lane 6). Mock = mock-
infected control. B. RT-PCR performed with the same intracellular RNA samples used for the 
northern blot analysis in A and the TBEV-specific primers listed in Table 1. cDNA synthesis 
was performed using a reverse primer that allowed the synthesis of the 5’ terminal part of 
TBEV genome, extending to the middle of the region coding for NS1. RT-PCR 1: PCR with 
primers binding to sequences in the region coding for the capsid protein (forward) and protein 
E (reverse), allowing detection of the wild-type genome but not replicon ∆C or ∆ME, which 
lack the forward and reverse primer-binding site, respectively. This PCR confirmed the 
presence of a full-length viral genome three endpoint passages after spiking the replicon 
mixture with a small amount of wild-type TBEV. RT-PCR 2: PCR with primers binding to the 
5’NCR (forward) and to the sequence coding for protein E (reverse), allowing detection of 
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wild-type virus (lane 1) and replicon ΔC (lane 3) but not ∆ME. Note the absence of the ∆C-
specific PCR product three endpoint passages after spiking with wild-type virus (lane 6). RT-
PCR 3: PCR with primers binding to the regions coding for the capsid protein (forward) and 
the NS1 protein (reverse), allowing detection of wild-type virus (lane 1) and replicon ΔME 
(lane 3), but not ∆C. Again, note the absence of the ∆ME-specific product three endpoint 
passages after spiking with wild-type virus (lane 6).  
 
Figure 5. Detection of recombinants using the recombination trap. A. Northern blot analysis 
of intracellular RNA. Left: Total cellular RNA was isolated from BHK-21 cells infected with 
wild-type TBEV (lane 1), mock-transfected cells (lane 2), cells infected using supernatants 
from the tenth passage after cotransfection with TBEV replicons ΔC + ΔE (lane 3) or ΔC + 
ΔME (lane 4), and control cells that were transfected separately with TBEV replicon ∆ME 
(lane 5), ∆E (lane 6), or ∆C (lane 7). Middle: The RNA was isolated from BHK-21 cells 
infected with wild-type WNV (lane 1), mock-transfected cells (lane 2), cells infected using 
supernatants from the tenth passage after cotransfection with WNV replicons ΔC + ΔE (lane 
3), and control cells that were transfected separately with WNV replicon ∆E (lane 4) or ∆C 
(lane 5). Right: The RNA was isolated from BHK-21 cells infected with wild-type JEV (lane 
1), mock-transfected cells (lane 2), cells that were infected using supernatants from the tenth 
passage after cotransfection with JEV replicons ΔC + ΔE in two separate experiments (lanes 3 
and 4), and control cells that were transfected separately with JEV replicon ∆E (lane 5) or ∆C 
(lane 6). B. RT-PCR for detection of recombinants. Lane designations are the same as in A. 
RT-PCR assays analogous to RT-PCR 1 in Fig. 4B were carried out using the same cellular 
RNA preparations used for the northern blot shown in A and the appropriate virus-specific 
"RT-PCR1" primers shown in Table 1. The forward and reverse primers in this assay bind to 
the missing regions of the ∆C and ∆E replicons, respectively, and an amplification product is 
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therefore only obtained when both of these sites are present on the same RNA molecule, as 
was observed with two JEV recombinants (lanes 3 and 4 of the right panel). 
 
Figure 6. Growth properties of JEV recombinants A. Schematic diagram of the JEV 
recombinants selected in experiments 1 and 2 (Fig. 5), named recombinant 1 and recombinant 
2, respectively. The 5’ part of the genome of recombinant 1 was derived from replicon ΔE and 
retained the original deletion. The crossover point is after the deletion, in the middle of the 
sequence coding for NS1. The 3' part of recombinant 1 begins with nucleotide 641 of the ∆C 
replicon (numbering corresponds to wild-type TBEV) and continues to the 3' end of the 
genome. The resulting genome thus contains two copies of most of the prM region. The 
genome of recombinant 2 differs from the wild-type genome by a short duplication in the C-
terminal portion of the capsid protein gene, resulting in a duplication of the cleavage site for 
the viral NS2B/3 protease. B. Morphology of plaques produced in Vero cells infected with the 
cloned recombinants. Recombinant 1 produced plaques similar to those of wild-type virus, 
whereas recombinant 2 produced only small plaques. C. Growth curves. Left: Growth kinetics 
of wild-type virus and recombinant viruses in BHK-21 cells after infection at an MOI of 0.1. 
Right: Growth kinetics of wild-type JEV and recombinant viruses in C6/36 mosquito cells 
after infection at an MOI of 0.1 
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TABLE 1. Primers used for RT-PCR 
 
 Forward primer Reverse primer  
TBEV Position in 
full-length 
genome 
Sequence  (5’→3’) Position in full-
length genome 
Sequence (5’→3’) Possible amplicons 
cDNA 
synthesis 
  NS-1 (nt 3700-
3679) 
ccaccacatagcgcaccagg   
RT-PCR 1 Capsid (nt 
214-235) 
caacccagagtccaaatgccaa  E (nt 2100-2081) cagctgcatctctatgaagc  full-length: 1887 nt, 
ΔC: none, ∆ME: none,  
ΔE: none 
RT-PCR 2 5’NCR (nt 1-
21) 
gcagcggttggtttgaaagag  E (nt 2100-2081) cagctgcatctctatgaagc  full-length: 2100 nt, 
ΔC: 1915nts, ΔME: 
none,  ΔE: none 
RT-PCR 3 Capsid (nt 
214-235) 
caacccagagtccaaatgccaa NS-1 (nt 3300-
3279) 
tccgagttatcagagaggag  full-length: 3087 nt, 
ΔC: none, ΔME: 589 nt, 
ΔE: 1600 nt 
 
WNV Position in 
full-length 
genome 
Sequence (5’→3’) Position in full-
length genome 
Sequence (5’→3’) Possible amplicons 
cDNA 
synthesis 
  NS-1 (nt 3700-
3680) 
tgacatagcgtaacacatcag   
RT-PCR 1 Capsid (nt 
164-187) 
gcgtgttgtccttgattggactga  E (nt 2100-2080) gggtggttccaattcaatcag  full-length: 1937 nt, 
ΔC: none, ΔE: none 
RT-PCR 2 5’NCR (nt 1-
20) 
agtagttcgcctgtgtgagc  E (nt 2100-2080) gggtggttccaattcaatcag  full-length: 2100 nt, 
ΔC: 1860 nt, ΔE: none 
RT-PCR 3 Capsid (nt 
164-187) 
gcgtgttgtccttgattggactga  NS-1 (nt 3300-
3280) 
gaagtcaatctctacccggcc  full-length: 3137 nt, 
ΔC: none, ΔE: 1636 nt 
      
JEV Position in 
full-length 
genome 
Sequence (5’→3’) Position in full-
length genome 
Sequence (5’→3’) Possible amplicons 
cDNA 
synthesis 
  NS-1 (nt 3407-
3381) 
ccagtcagtgatcaactttcca
ctgtcag  
 
RT-PCR 1 Capsid (nt 
166-190) 
tattcccactagtgggagtgaag
ag  
E (nt 2130-2110) ctacgatgtaggagtctccga  full-length: 1995 nt, 
ΔC: none, ΔE: none 
RT-PCR 2 5’NCR (nt 48-
67) 
tcgagagattagtgcagttt  E (nt 2130-2110) ctacgatgtaggagtctccga  full-length: 2082 nt, 
ΔC: 1860 nt, ΔE: none 
RT-PCR 3 Capsid (nt 
166-190) 
tattcccactagtgggagtgaag
ag  
NS-1 (nt 3079-
3057) 
ccagtacgacaagtcactatg
gac  
full-length: 2913 nt, 
ΔC: none, ΔE: 2722 nt 
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Manuscript 2 
 
Trans-complementing replicon pairs of TBEV evolve by the acquisition of 
spontaneous deletions but not recombination to infectious virus 
 
Abstract 
 
Many RNA viruses show high levels of genetic diversity and recombination can be frequently 
observed. Faviviruses seem to exhibit an unusually low propensity for homologous 
recombination as demonstrated in a recent study. Among three different flaviviruses (tick-
borne encephalitis virus, TBEV, West Nile virus, WNV, Japanese encephalitis virus, JEV) 
tested in a ‘recombination trap’ consisting of pairs of overlapping replicons, none underwent 
homologous recombination which would habe generated infectious wild-type genomes. Only 
JEV yielded infectious genomes with unnatural genome organization by an aberrant 
recombination process. To further investigate the evolution of such trans-complementing 
replicon pairs upon repeated passages, we designed TBEV replicons which shared an 
exceptionally long (2kb) sequence overlap between the deletions in the genes encoding 
protein C or E, respectively. The two replicons could complement each other in the 
production of virus particles and could be serially passaged. As observed with shorter overlap 
regions, no recombination generating infectious full-length genomes was observed. 
Surprisingly, however, the replicon carrying a deletion in the E gene spontaneously extended 
this deletion to reach into the NS1 gene. These new mutants were incapable to replicate by 
themselves, but in the presence of the other replicon or wild-type virus, they were efficiently 
replicated and packaged. Cotransfection with wildtype virus proved that they behaved 
functionally as defective interfering particles. This represents the first characterization of DI 
RNAs of TBEV. Taken together our data demonstrate the ability of TBEV to undergo 
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intramolecular recombination but suggests that intermolecular recombination between 
different TBEV genomes is an unlikely event. 
 
 
Introduction 
 
TBEV belongs to the tick borne group of the genus flavivirus. Both experimental (Manuscript 
1) and phylogenetic studies (147) on RNA recombination of tick-borne viruses failed to 
provide evidence for recombination to occur with this virus.. The close antigenic and 
phylogenetic relationships and the characteristics of their geographic distribution led to the 
proposal that viruses of this group had evolved in a gradual manner by the acquisition of point 
mutations (40). This contrasts with mosquito-borne flaviviruses which appeared to have 
evolved in a more discontinuous fashion which is demonstrated by the identification of 
recombinant genomes of JEV, all four dengue viruses and St.Louis encephalitis virus 
(Manuscript 1)(57, 143, 147, 148). In addition to recombination to full-length viruses, RNA 
viruses can generate recombinant subgenomic deletion RNAs designated defective interfering 
RNA (DI RNA). Such DI RNAs have been found in cell cultures persistently infected with 
west nile virus (WNV), murray valley virus and JEV (15, 30, 86, 145, 155) but not with 
TBEV. It has been suggested that DI RNAs are generated according to the copy choice model 
of RNA recombination (17, 87, 116) (King, A.M.Q. 1988. Genetic recombination in positive 
strand RNA viruses, p150-185. In E. domingo, J.J. Holland, and P. Ahlquist (ed.), RNA 
genetics II. CRC Press, Inc., Boca Raton Fla.) in which the viral RNA dependent RNA 
polymerase (RdRp) jumps either within (intramolecular) or between (intermolecular) 
templates during RNA replication. DI RNA genomes contain large internal deletions but 
retain all cis-acting regulatory sequences required for replication and packaging of the RNA. 
Their RNA replication depends on enzymes and structural proteins, provided by infectious 
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helper virus. Importantly, DI RNA can interfere with the replication of viruses able to act as 
helpers (121)and are most efficiently generated under conditions in which many infectious 
virus genomes simultaneously infect the same cell (55)  
TBEV is a single stranded positive-sensed RNA virus. Its genome encodes only a 
single open reading frame which is translated into a polyprotein. Posttranslational cleavages 
by viral and host proteases yield three structural proteins: the capsid (C) protein, membrane 
(M) and envelope (E), as well as seven non-structural proteins that are essential for viral 
replication. Replicons, defined as a self-replicating, non-infectious RNA molecules, can be 
generated by deleting parts or all of the region coding for the structural proteins C, prM and E. 
In contrast to DI RNA genomes, replicons are capable of autonomous RNA replication. 
Recently, we have developed a recombination trap that favors the selection and sensitive 
detection of recombination products (Manuscript 1). This system involves two different 
replicons with reciprocal deletions of different parts of the structural region. Upon 
introduction of both replicons into the same host cell, each replicon provides the structural 
protein(s) that are missing in the other one. Complementation leads to packaging of both 
defective RNA genomes in two different viral particles and further rounds of infection are 
possible at a multiplicity of infection that allows sufficient coinfection. Possible recombinant 
full-length infectious viruses were shown to outgrow complementing replicons in limiting 
dilution passages, because they do not depend on coinfection (Manuscript 1). Using this 
system, we could demonstrate that replicons of JEV were able to recombine to full-length 
viruses by aberrant homologous recombination. In contrast replicons of TBEV and WNV 
sharing the same length of homologous sequence did not show evidence of recombination. In 
the here described study we wanted to further explore the evolutionary boundaries of tick-
borne encephalitis virus in this experimental setting. Two replicons which shared almost 2kb 
homologous sequence where crossover yielding wild-type virus could occur were constructed 
and tested for their propensity for recombination. Despite selecting conditions for full-length 
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virus, one of the complementing replicons evolved by the acquisition of large internal 
deletions. These results provide evidence that TBEV exhibits a greater propensity for 
intramolecular adaptation than for recombination between different RNA genomes.  
 
Materials and Methods 
 
Cells. BHK-21 cells were grown in Eagle’s minimal essential medium (Sigma) 
supplemented with 5% fetal calf serum (FCS), 1% glutamine and 0.5% neomycin (growth 
medium) and maintained in Eagle’s minimal essential medium supplemented with 1% FCS, 
1% glutamine, 0.5% neomycin and 15 mM HEPES, pH 7.4 (maintenance medium).  
 
Plasmids and cloning procedures. Plasmid pTNd/c, used for generating infectious 
TBEV, contains a full-length genomic cDNA insert of TBEV strain Neudoerfl (GenBank 
accession number U27495) cloned in plasmid pBR322 (96). RNA transcribed from this 
plasmid was used as the TBEV wild-type virus control. Plasmid pTNd/5’ contains a 5’ cDNA 
fragment of the same viral genome (96). Full-length DNA templates for in vitro transcription 
of TBEV plasmids were generated as described previously (77). Plasmid pTNd/ΔDIII was 
constructed using the following primers: ttttcTACGTAcaccaagaaaggcatagaaagac (SnaBI 
restriction site) and gcattATCGATagtgtgactagcaggccatg (ClaI restriction site). pTNd/5’ was 
used as template for the PCR, generating a SnaBI – ClaI fragment lacking domain III of the E 
protein. This fragment was cloned into plasmid pTNd/c generating a full-length replicon 
lacking the sequence coding for domain III of E (aa302-395) as well as additional 10 aa of the 
stem region of protein E (or nucleotides Δ1884-2187 respectively). pTNd/c-ΔM-E-Ns1 and 
pTNd/c-ΔE-Ns1 were cloned using the amplicon of the RT-PCR-3 of RNA isolated after 6 
serial passages of infectious combination ΔC + ΔDIII at limiting dilution. The PCR was 
carried out with primers that excluded the amplification of ΔC (see RT-PCR). The resulting 
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amplicons were digested with MluI and ClaI and cloned into pTNd/5’. E. coli colonies were 
screened for TBEV virus sequences with the following primers: forward primer 
corresponding to nucleotides 43-63, reverse primer corresponding to complementary 
nucleotides of 3170-3150. Positive clones were subjected to sequence analysis and revealed 
that of 40 positive clones 1 clone contained the original ΔDIII deletion, 4 contained a deletion 
of  ΔE-Ns1 (nucleotides 986-3097) and the remaining 35 contained a deletion of ΔM-E-Ns1 
(nucleotides 690-2999). One of ΔE-Ns1 and one of ΔM-E-Ns1 positive pTNd/5’ clones were 
further digested with SalI and ClaI and the resulting fragment was cloned into pTNd/c 
generating pTNd/c-ΔE-Ns1 and pTNd/c-ΔE-Ns1 or into pTNd/c-ΔM-E-eGFP(42) resulting in 
pTNd/c-ΔE-Ns1-eGFP and pTNd/c-ΔE-Ns1-eGFP respectively. 
 
RNA transfection. In vitro transcription and transfection of BHK-21 cells by 
electroporation were performed as described previously (79, 96, 114). RNA was synthesized 
(80)reagents of the T7 Megascript kit (Ambion) according to manufacturer’s protocol. The 
template DNA was digested by incubation with DNase I, and the quality of the RNA was 
checked by electrophoresis in a 1% agarose gel containing 6% formalin. RNA was purified 
using an RNeasy Mini kit (Qiagen) and quantified spectrophotometrically. Equimolar 
amounts of RNA were then introduced into BHK-21 cells by electroporation using a Bio-Rad 
Gene Pulser (1.8kV, 25µF, 200Ώ). For cotransfections, equal amounts of RNA (~1.1 1012 
copies) of each construct were mixed before electroporation. 
 
Immunofluorescence assays. Twenty-four hours after transfection or infection, BHK-
21 cells were fixed for 20 min with 4% paraformaldehyde in PBS (pH 7.4) and then washed 
two times for 5 min with PBS (pH 7.4) and permeabilized with ice-cold methanol for 6 min at 
-20°C. After three washes with PBS (pH 7.4) and blocking with 3% BSA in PBS (pH 7.4) for 
30 min at room temperature, intracellular E protein was visualized by sequential incubation 
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with a monoclonal mouse antibody against E (1E9) (48) and  a Rhodamine-Red-X-conjugated 
anti-mouse IgG antibody (Jackson Immune Research Laboratory). Simultaneously, eGFP 
fluorescence was enhanced with a polyclonal rabbit-antibody against GFP (Abcam: ab6556) 
and successive incubation with fluorescein-isothiocyanate (FITC)-conjugated anti-rabbit IgG 
antibody (Jackson Immune Research Laboratory).  
 
Endpoint passages. Supernatants of infected cells were sequentially diluted, and 200 
µl of each dilution was applied to fresh BHK-21 cells grown in 24-well plates (Nunc). After 
three days, half of the medium was replaced by fresh medium, and after six days, protein E 
released into the supernatant  was detected using a four-layer enzyme-linked immunosorbent 
assay (ELISA)(53). After six days, the highest dilution yielding a positive signal in ELISA 
was cleared of cell debris, sequentially diluted and used for infection of fresh BHK-21 cells. 
Intracellular RNA genomes were analyzed at different passage numbers by northern blotting 
and RT-PCR (see below) 
 
Northern blot analysis. Template DNA for synthesis of RNA probes for northern 
blotting was generated using the following primers and templates: TBEV: template pTNd/c 
and primers agagagcagaagggattga  and tacttaatacgactcactataggtgtgcaagacacccttg generated a 
probe binding to nucleotides 4093-4773 in wild-type virus. After phenol-chloroform 
purification of the template DNA, the T7 promoter sequence (underlined) fused to each 
reverse primer allowed RNA synthesis using a T7 MAXIscript In Vitro Transcription Kit 
(Ambion). The probe RNA was labeled by using 0.4 µl of 10 mM Bio-11-UTP (Ambion) 
instead of UTP. Probe RNA was separated from free nucleotides using Micro Bio-Spin 30 
columns (BioRad). 
Cytoplasmic RNA was extracted from BHK-21 cells 24 hours after transfection or 
infection. Ten µg of total RNA was applied to a 1% Agarose gel and northern blotting was 
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carried out according to the instructions of the NorthernMax-Gly Kit (Ambion), blotted RNA 
was detected using a BrightStar BioDetect Kit (Ambion). 
 
RT-PCR. BHK-21 cells were seeded into 25-cm2 tissue culture flasks. The monolayer 
of cells was infected with 2 ml supernatant of wild-type virus or infectious combination of 
replicons. After 24 hours post infection cytoplasmic RNA was extracted using RNeasy ® 
Mini Kit (Qiagen). Further cDNA was synthesized using a specific primer to TBEV 
(sequence reverse complementary to nucleotides 3700-3679 of plasmid pTNd/c) with the 
cDNA Synthesis system of ROCHE. Wild-type, replicon or possible recombinant genomes 
were detected using primers binding to a sequences present only in wild-type virus (RT-PCR 
1) or replicon ΔC (RT-PCR) or replicon ΔDIII (RT-PCR 3) (see table 1) using the 
Advantage® HF2 PCR Kit (Clontech). As size control separately transfected control RNA of 
wild-type virus and each replicon RNA was used. Further, each obtained amplicon was 
subjected to sequence analysis (as described before (79)). 
 
Table. 1. Primers used for RT-PCR analysis. 
TBEV Position in 
full-length 
genome 
Forward (5’→3’) Position in full-
length genome 
Reverse (5’→3’) possible amplicons 
cDNA 
synthesis 
  NS-1  
(nt 3700-3679) 
ccaccacatagcgcaccagg   
RT-PCR 1 Capsid  
(nt 214-235) 
caacccagagtccaaatgccaa  E  
(nt 2100-2081) 
cagctgcatctctatgaagc  full-length: 1887 nts 
ΔC: none 
ΔDIII: none 
RT-PCR 2 5’NCR  
(nt 1-21) 
gcagcggttggtttgaaagag  E  
(nt 2100-2081) 
cagctgcatctctatgaagc  full-length: 2100 nts 
ΔC: 1915nts 
ΔDIII: none  
RT-PCR 3 Capsid   
(nt 214-235) 
caacccagagtccaaatgccaa NS-1  
(nt 3300-3279) 
tccgagttatcagagaggag  full-length: 3087 nts 
ΔC: none 
ΔDIII: 2784 nts 
 
 
Quantitative PCR. RNA replication and export kinetics were analyzed by 
quantitative real-time PCR (qPCR). For the determination of intracellular RNA copy numbers, 
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cells were collected at individual time points and counted in a Casy TT cell counter (Schärfe 
Systems). Cytoplasmic RNA was purified from a defined number of cells using an RNeasy 
Mini kit and subjected to qPCR. Primer and probes of each qPCR are listed in table 2. The 
same conditions were used for each qPCR as described in a previous study (79). For the 
measurement of viral RNA export, aliquots of supernatants were harvested at the same time 
points as those used for intracellular RNA levels and were cleared from cell debris and 
insoluble material by centrifugation. Next, 140 µl of the supernatant was incubated with 35 µl 
5x RLN lysis buffer (250 mM Tris-Cl, pH 8.0, 700 mM NaCl, 7.5 mM MgCl2, 2.5% [vol/vol] 
Nonidet P-40, 5 mM DTT) for 1 min on ice to break up the viral membrane. Viral RNA was 
further isolated from one-fifth of each lysate, again using an RNeasy Mini kit by following the 
protocol utilized for intracellular RNA purification. One-fifth of the isolated RNA then was 
used as a template for cDNA synthesis using an iScript cDNA synthesis kit (Bio-Rad) 
according to the manufacturer's protocol. An aliquot corresponding to 7 µl of the original cell 
culture supernatant was subjected to qPCR using the same conditions as those for the 
quantification of intracellular RNA (79). The amounts of intra- and extracellular RNA were 
quantified by the comparison of the results to a standard curve. The standard curve was 
prepared by using a serial 10-fold dilution of spectrophotometrically quantified, purified, in 
vitro-synthesized RNA. The total amount of RNA present in each culture flask (intra- and 
extracellular) was further calculated from the measured RNA concentrations to determine the 
percentage of total RNA exported into the supernatant. 
 
Table. 2. Primers used for qPCR analysis. 
qPCR in NS5 5’ → 3’ Position in wild-type 
sequence 
forward Primer GAAGCGGAGGCTGAACAACT nt 7701-7720 
reverse Primer TTGTCACGTTCCGTCTCCAG nt 7781-7762 
Probe TGTGTACAGGCGCACCGGCA nt 7740-7759 
 
qPCR in Capsid 
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forward Primer CAAATGGGCTTGTGTTGATG nt 233-252 
reverse Primer GCACTCACCGTCCTTTTGAT nt 383-364 
Probe GAAGGCGTTCTGGAACTCAG nt 309-328 
 
qPCR in DIII of protein E 
forward Primer CAGTGGGCATGATACAGTGG nt 1932-1951 
reverse Primer AATTGTTGGGTTTGGCGTTA nt 2064-2045 
Probe AAGCCCTGTAGGATCCCAGT nt 1978-1997  
 
 
Results 
 
TBEV replicons with long redundant sequences can complement each other. 
Earlier studies have shown that two replicons with deletions of different structural proteins 
(protein C or E) can produce infectious virus particles when they are present in the same cell. 
In this study, we further exploited this approach by constructing two replicons with different 
deletions in the region coding for the structural proteins and a 2kb long overlapping region 
between the respective deletions where recombination would generate full-length viral 
genomes. Replicon ΔC contained a large deletion (62aa) in the region coding for the capsid 
protein (78)(figure 1) and replicon ΔDIII contained a small deletion in protein E comprising 
the region coding for domain III (figure 1). The sequences between the two engineered 
deletions are present on both replicons and could potentially comprise sequence elements that 
facilitate template switch for intermolecular recombination to full-length virus. Although each 
replicon lacked an essential part of the structural region, all three structural proteins could be 
provided when both replicons were present in the same cell: Capsid (encoded on replicon 
ΔDIII), prM (on both replicons) and E (only on replicon ΔC). To test this hypothesis, both 
mutants were cotransfected into BHK-21 cells and a first passage was dascarried out with 
undiluted supernatant. The observation of infected cells stained with polyclonal TBEV serum 
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indicated that trans-complementation between replicon ΔC and ΔDIII took place and 
infectious virus particles were produced (data not shown).  
Selection of recombination products. Complementing replicons of TBEV were 
shown to be outgrown by few infectious units of full-length infectious virus in limiting 
passages (data not shown). Hence, to select for infectious full-length viruses, the following 
passages of complementing replicons ΔC and ΔDIII were done by serial dilution of 
supernatants of infected cells and determination of the endpoint dilution by ELISA after 6 
days post infection. Typically, wild-type virus under these conditions grew to titers 106 to 107 
whereas the replicon pairs achieved titers of only 102 to 103. This can easily be explained by 
the fact that in the case of the replicons producing cells must be double infected. Upon 
passages, recombination to full length genome would have been expected to lead to growth to 
higher virus titers. However, over a course of 10 passages, no such shift to higher virus titers 
was observed suggesting that no recombination had occurred. To confirm this assumption, 
intracellular viral RNA was analyzed by northern blot analysis and RT-PCR. In the northern 
blot analysis wild-type virus (figure 2a lane 1) or separately transfected control RNA of 
replicon ΔC (figure 2a lane 4) and ΔDIII (figure 2a lane 5) produced a single band. As 
expected, only one band was visible after cotransfection of the two replicons ΔC and ΔDIII 
(figure 2a lane 2) because of almost equal genome size of the two constructs. Surprisingly, 
after 6 passages with these complementing replicons, northern blot analysis revealed two 
bands (figure 2a lane 3). This indicated that a new RNA genome smaller than the two original 
replicons had emerged. Interestingly, the smaller band was more prominent than the larger, 
indicating a selective advantage of the smaller genome. 
Complementing TBE replicons evolve by intramolecular recombination. As a 
more sensitive and precise means of assessing which recombinant RNA molecules were 
present in the population, we devised a RT-PCR assay for detecting sequence rearrangement 
in the structural regions of the original complementing replicons ΔC and ΔDIII. This was 
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accomplished by first making a cDNA copy of approximately the 5' half of the isolated 
intracellular RNA (extending to the middle of the NS1 gene) and then attempting to amplify a 
portion of this cDNA using different combinations of primers (for details see material and 
methods). First, the absence of RNA genomes encoding all three structural proteins on one 
molecule was confirmed. RT-PCR 1 with primers binding to sequences absent on both 
replicons (in the capsid and e genes) yielded a product only for cells infected with wild-type 
virus (figure 2b lane 1) but not for any replicon RNA (figure 2b lanes 2 and 3). The lack of 
amplicons from cells infected with complementing replicons ΔC and ΔDIII showed that no 
full-length virus genome were present even after repeated copassages (figure 2b lane 4).  
Subsequently, each replicon was specifically identified with appropriately designed 
PCR assays. RT-PCR-2 with primers not binding to replicon ΔDIII (reverse primer in E gene) 
yielded the expected product of replicon ΔC (figure 2b lane 3) which is smaller than that of 
wild-type virus (figure 2b lane 1). After copassages replicon ΔC was still present (figure 2b 
lane 4). To specifically detect replicon ΔDIII RT-PCR-3 was designed with primers not 
binding to replicon ΔC. Again, amplicons of this replicons (figure 2b, lane2) were smaller 
than that of wild-type virus (lane 1). Interestingly, after co-passages of ΔC and ΔDIII (figure 
2b lane 4) products were obtained that were smaller than the expected size for replicon ΔDIII. 
Cloning and sequencing of these PCR products (for details see material and methods) 
revealed that the originally designed deletion within ΔDIII had been significantly extended in 
these emerged mutants: These new mutants were designated ΔE-NS1 and ΔME-NS1 and their 
organization is shown in figure 1. Mutant ΔE-NS1 contained an internal deletion lacking 
nucleotides 986 to 3097. The deleted sequence comprised the whole sequence coding for 
protein E and part of the non-structural protein NS1 and was therefore designated ΔE-NS1 
(figure 1). Mutant ΔME-NS1 contained an internal deletion of nucleotides 690 to 2999. The 
deletion comprised the mature protein M as well as the whole sequence coding for protein E 
as well as part of NS1 (figure 1). In summary, both emerged RNAs contained an enlarged 
91 
deletion compared to the original replicon ΔDIII. Both deletions affected the sequences 
coding for protein NS-1. 
Emerged RNAs show characteristics of defective interfering RNAs. To examine 
whether the emerged mutants exhibit characteristics of DI RNA the deletions were introduced 
into the cDNA clone of full-length TBE virus (see materials and methods and figure 1). Then, 
the replication competence of each mutant in the absence of the complementing replicon ΔC 
was analyzed. BHK cells were transfected with full-length mutant RNA and intracellular 
RNA was quantified by quantitative PCR analysis.  
As shown in figure 3a, transfected RNA of ΔE-NS1 and ΔME-NS1 as well as of a replication 
deficient mutant ΔNS5 which contained a deletion in the region coding for the viral 
polymerase (79) were shown to decrease over time. In contrast, replicon ΔDIII and a replicon 
ΔR88 which exhibits a RNA replication level like wild-type virus (32) were capable of 
accumulating viral RNA within transfected cells. This confirmed that the two emerged 
mutants were incapable of autonomous RNA replication. 
Furthermore, the effect of the emerged mutants on the replication of infectious wild-type virus 
was monitored (figure 3b). Equal amounts of wild-type virus RNAwere co-transfected with 
each mutant. Viral titers were determined by focus assay and revealed that co-transfection of 
wild-type virus with either mutant resulted in a reduced titer. These results demonstrated that 
both emerged mutants could not!!! replicate without enzymes provided by helper virus and 
interfered with replication of infectious virus, both of which are characteristics of DI RNA.  
DI RNAs are infectious by complementation with replicon ΔC. To analyze whether 
the observed DI RNAs ΔE-NS1 and ΔME-NS1 can complement replicon ΔC and produce 
infectious virus particles the mutants were cotransfected with replicon ΔC. To allow separate 
detection of mutant RNA genomes and replicon ΔC DI RNAs were tagged with eGFP 
encoded in a second open reading frame in the 3’NCR as described previously (figure 1). 
Then, each GFP tagged DI RNA was co-transfected with replicon ΔC. Replication of DI 
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RNAs was monitored by the expression of eGFP and replication of replicon ΔC by the 
expression of protein E. As expected, transfection of replicon ΔC yielded cells expressing 
protein E (figure 4) and transfection of DI RNA genomes ΔE-NS1-eGFP and ΔME-NS1-
eGFP resulted in cells negative for eGFP expression which further confirmed the replication 
deficiency of these mutants. However, co-transfection of replicon ΔC and either ΔE-NS1-
eGFP or ΔME-NS1-eGFP yielded cells not only expressing protein E but also eGFP. This 
indicated that replicon ΔC could restore replication of the DI RNAs when both were present 
in the same cells.  
Interestingly, after transfer of supernatants onto fresh cells, cells expressing only protein E but 
not eGFP, as well as cells expressing E and eGFP could be observed (figure 4). However, as 
expected, there were no cells expressing eGFP in the absence of protein E expression 
confirming that the eGFP expressing deletion mutants were not capable of self-replication in 
the absence of a helper replicon or virus. In addition, cells expressing both proteins indicated 
that both genomes were packaged into viral particles and coinfection with two viral particles 
containing different viral genomes resulted in another round of trans-complementation.  
RNA replication and packaging of DI RNAs is complemented by replicon ΔC. To 
confirm that replicon ΔC is able to restore the replication of the DI RNAs which is required 
for trans-complementation, a quantitative PCR analysis was established. Primers and probes 
directed to the region absent on replicon ΔC allowed exclusive monitoring of replication and 
packaging of replicon ΔDIII or DI RNA genomes. Analysis of intracellular RNA revealed that 
RNA replication of DI RNA mutants ΔE-NS1 and ΔME-NS1 was restored to the level of the 
original replicon ΔDIII after cotransfection with replicon ΔC (figure 5a). Further, 
quantification of RNA released from cotransfected cells showed that DI RNAs were exported 
as efficiently as replicon ΔDIII after cotransfection with replicon ΔC (figure 5c). Concluding, 
replicon ΔC was able to restore RNA replication of DI RNA genomes, probably by providing 
a functional NS-1 protein. This again led to the presence of two replicating genomes coding 
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for all three necessary structural proteins and thus packaging of the DI RNAs ΔE-NS1 and 
ΔME-NS1. 
DI RNAs interfere with RNA replication of replicon ΔC but increase its 
packaging efficiency. DI RNAs replicate by means of enzymes provided by infectious helper 
virus with which they interfere. To assess a possible inhibiting effect of DI RNAs on the 
replication of replicon ΔC a quantitative PCR analysis with primers and probe directed to the 
region coding for domain III of protein E was designed. This allowed the specific detection of 
replicon ΔC excluding all other mutant genomes. As shown in figure 5b, transfection of 
replicon ΔC alone or together with ΔDIII resulted in similar replication efficiencies, 
indicating that replicon ΔDIII did not interfere with the replication of replicon ΔC. In contrast 
cotransfection of replicon ΔC with one of the emerged DI RNAs, led to a decreased 
replication of replicon ΔC by at least one log (figure 5b). This result showed that mutants ΔE-
NS1 and ΔME-NS1 not only interfered with replication of infectious full-length genomes but 
also with RNA replication of replicon ΔC. Despite the decreased replication, analysis of 
exported RNA revealed that almost equal amount of replicon ΔC was exported disregarding if 
the complementing partner was replicon ΔDIII or one of the emerged DI RNAs (figure 5d). 
Calculation of the export efficiency showed that RNA of replicon ΔC was exported more 
efficiently when the complementing partner was one of the emerged DI RNAs (figure 6). This 
means, that although DI RNA interfere with RNA replication of replicon ΔC, the overall 
efficiency of trans-complementation is not inhibited because of better packaging of replicon 
ΔC. Taken together, despite the presence of two viral genomes with long homologous 
sequences replicating in the same cell and the low efficiency of trans-complementation 
between the two replicons, an infectious full-length virus generated by intermolecular 
recombination was not detected in any passage. On the contrary, one of the two 
complementing replicons evolved by acquisition of large internal deletions, possibly by an 
intramolecular recombination process. The emerged mutants ΔE-NS1 and ΔME-NS1 
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exhibited classical DI RNA properties meaning they interfered not only with replication of 
infectious wildtype virus but also with RNA replication of replicon ΔC. However, in the 
trans-complementation system, this was compensated by an increased packaging efficiency of 
replicon ΔC. In summary, our data presents the first characterization of DI RNA of TBEV and 
suggests that TBEV has an extremely low propensity for intermolecular recombination. 
 
Discussion 
 
Unlike other RNA viruses, flaviviruses seem to have a low propensity for 
intermolecular recombination. Only recently we were able to provide the first direct proof for 
RNA recombination between two flavivirus genomes. Using a recombination trap designed to 
detect even rare recombination events we obtained two recombinants generated by 
intermolecular recombination between two complementing replicons of JEV. The established 
recombination trap consisted of pairs of self-replicating subgenomic RNAs (replicons) that, 
lacked different portions of the structural proteins. Individually, replicons can not produce 
infectious virions but in this system they could complement each other in trans and thus be 
propagated together in cell culture over multiple passages. Any infectious viruses with intact, 
full-length genomes that were generated by possible recombination of the two replicons 
would be selected and enriched by endpoint-dilution passage, as was demonstrated in spiking 
experiments. Interestingly, no viable recombinants were detected between replicons of WNV 
or TBEV despite the presence of 0,5kb homologous sequences where crossover could have 
occurred. To allow more detailed investigation of the types of recombination events that 
TBEV is capable of undergoing as well as their relative frequencies a similar approach was 
taken in this analysis: To provide optimal conditions for intermolecular recombination, we 
constructed two replicons of TBEV that shared 2kb long homologous sequences and only 
poorly complemented each other in virus particle production which would favor the selection 
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of recombinant full-length genomes even with reduced growth properties. Surprisingly, 
despite our extensive efforts we could not detect intermolecular recombination to infectious 
full-length viruses.  
On the contrary, one of the two analyzed complementing replicons of TBEV adapted 
by the acquisition of large internal deletions. The loss of sequences not required for 
complementation in-cis resulted in two subgenomic RNAs that contained in frame deletions 
of the entire E gene and different portions of the flanking regions including the region coding 
for the N-terminal NS-1 protein. Strikingly, the lack of protein E and N-terminal part of NS-1 
are features shared by all DI RNAs described for flaviviruses. Of 43 different DI RNAs 
described for JEV and MVE, the majority contained deletions affecting the regions coding for 
prM, E and NS-1 while only few also affected the region coding for protein C(145, 155). 
Interestingly, the deletions never affected the C-terminal part of NS-1. This is in good 
agreement with the observation that NS-1 can only be complemented in-trans efficiently if the 
C-terminal part is retained (69). This overall similar molecular organization of DI RNA of 
different flaviviruses and the fact that all deletions are in-frame suggests that DI RNAs are not 
generated by recombination hot spots but are selected because of their properties including 
their ability to be complemented in-trans.  
Generally, DI RNAs emerge in association with infectious wild-type virus and 
interfere with its infectivity while depending on the help of the wild-type virus for RNA 
replication. Here, the observed RNA genomes ΔME-NS-1 and ΔE-NS-1 showed classical DI 
RNA properties in association with wild-type virus. However in the two component trans-
complementation system, infectivity depended on the presence of these mutants. Even though 
they interfered with the RNA replication of the non-infectious helper genome of replicon ΔC, 
the loss of sequences on the mutants not essentially required for complementation seemed to 
be advantageous. One possible reason is that the remaining part of protein E encoded by 
replicon ΔDIII is impedimental in assembly or when packaged into virions.  
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The generation of DI RNAs is believed to follow a similar or identical mechanism as 
true intermolecular recombination. One obvious example is the generation of DI RNA of 
Sindbis virus, in which tRNA sequences are incorporated at the 5’ terminus of the virion RNA 
(146). Another example is provided by structural analysis of a DI RNA of influenza virus 
(34). The analyzed RNA has been shown to consist of several discontinuous regions, some of 
which were derived from influenza virus RNA-1 and others from RNA-3. Thus, it may 
represent a true recombinant RNA between two different RNA molecules, although both 
RNAs belong to the same virus. Moreover, in Coronavirus it was shown that recombination 
occurred more frequently within a hypervariable region (5), in which deletions commonly 
occur after virus passage in tissue culture or animals. Therefore we hypothesize that inter-
molecular recombination, the acquisition of internal deletions or the generation of DI RNAs 
are related. However, considering that in this study DI RNAs were generated despite 
conditions favoring the selection of full-length viruses generated by intermolecular 
recombination suggests that TBEV polymerase exhibits a lower propensity for inter- than for 
intramolecular recombination. This assumption is supported by the fact that under 
experimental conditions true intermolecular recombination has only been demonstrated for 
JEV (Manuscript 1). In contrast, DI RNAs were identified not only in cells persistently 
infected with JEV (145, 155) but also with MVE (86) and WNV(15). In addition, infectious 
West Nile or TBE viruses can quickly acquire large internal deletions or duplications (80, 
127) probably by a mechanism similar to intramolecular recombination. 
One possible explanation for this different propensity of inter- or intra-molecular 
recombination may be provided by the organization of the flavivirus replication complex. For 
flaviviruses RNA replication occurs in association with ∼50–70 nm diameter membranous 
vesicles or spherules (151). It has been speculated that a single spherule contains only one or 
few (–) RNA templates for replication (81, 151) which would explain the low probability for 
template switches between different viral genomes. Another explanation may be that the 
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flavivirus replication complex itself accounts for the low propensity for template switches by 
a strong association to negative-sense template RNA. 
In addition to RNA recombination, the described trans-complementation system 
allowed insights into flavivirus packaging. Separate detection of both involved viral RNAs 
and calculation of export efficiencies revealed that no direct correlation between RNA 
replication and packaging efficiency existed in this trans-complementation system. Although 
mutants ΔE-NS1 and ΔME-NS1 diminished the RNA replication of replicon ΔC, it was 
exported to similar levels as when the complementing partner was replicon ΔDIII. This means 
that the packaging efficiency of replicon ΔC was not determined by sequences in-cis but by 
the in-trans complementing helper RNA suggesting that no RNA sequences but the way the 
three structural proteins are provided determined the packaging efficiency in this trans-
complementation system. Notably, replicon ΔDIII did not affect the RNA replication of 
replicon ΔC. This suggests that two flaviviruses do not compete with each other on the level 
of RNA replication when both are capable of autonomous replication and that the interfering 
effect of DI RNA rests on the limited access of functional protein NS-1. In summary, we 
provide the first characterization of DI RNAs of TBEV and confirm that flaviviruses have an 
extremely low – if any – propensity for intermolecular recombination and show that TBEV 
has a higher propensity for intramolecular recombination. It will be interesting to determine 
what constraints are responsible for this discrepancy. Nevertheless, the general low propensity 
of TBEV to generate recombinants by intermolecular recombination makes this virus a 
reliable tool for vector development or live vaccines. 
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Figure Legends 
 
Figure 1. Top: Schematic drawing of a full-length flavivirus genome. Below: Shematical 
blow up of the structural region of TBEV replicons ΔC (76), and replicon ΔDIII as well as DI 
RNA genomes ΔE-NS1 and ΔME-NS1. Box. An internal ribosomal entry site (IRES) driven 
translation element of eGFP was cloned in the 3’noncoding region of the emerged DI RNAs. 
Deletions are indicated by doted lines and the missing nucleotides are indicated within each 
deletion. Nucleotide numbers refer to the position in each respective wild-type virus 
sequence. The length of homologous sequences allowing recombination yielding full-length 
virus is indicated at left. C: capsid protein; pr: pr part of protein prM; M: mature protein prM; 
E: protein E, NS: non-structural protein; NCR: non coding region 
 
Figure 2. A. Northern blot analysis of intracellular viral RNA: Lane 1. RNA of cells infected 
with wild-type virus. Lane 2: RNA of cells transfected with replicon ΔC as well as ΔDIII. 
Lane 3: RNA of cells infected with supernatant containing replicons ΔC and ΔDIII after 6 
passages. Lane 4: RNA of cells transfected with replicon ΔC alone. Lane 5: RNA of cells 
transfected with replicon ΔDIII alone. Lane 6: mock transfected cells. B. RT-PCR analysis of 
intracellular RNA. RT-PCR-1 was performed with primers binding to sequences absent on 
both replicons. RT-PCR-2 was performed with primers allowing amplification of replicon ΔC 
RT-PCR 3 was performed with primers binding to sequences absent of replicon ΔC. Lane 1. 
RNA of cells infected with wild-type virus. Lane 2: RNA of cells transfected with replicon 
ΔDIII. Lane 3: RNA of cells transfected with replicon ΔC alone. Lane 4: RNA from cells 
infected with supernatant containing replicons ΔC and ΔDIII after 6 passages Lane 5: RNA of 
cells transfected with cloned RNA of ΔE-NS-1. Lane 6: RNA of cells transfected with cloned 
RNA of ΔME-NS-1. Lane 7: RNA of mock transfected cells. 
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Figure 3. A. Quantitative PCR with primer and probes binding to sequences coding for NS-5 
of intra-cellular RNA after RNA transfection. ΔR88 is a non-infectious TBE virus with a 
single amino acid deletion which replicates to wild-type virus levels. ΔNS5 lacks the 3’ 
terminal part of the TBEV genome including the sequences coding for NS5 and serves as a 
control for a non-replicating viral genome. B. Analysis of the interfering effect of the emerged 
RNAs on wild-type virus. Cells were transfected with wild-type virus and equal amounts of 
ΔE-NS-1 or ΔME-NS-1. Infectious units were quantified by focus assay. 
 
Figure 4. Co-immunofluorescense staining with antibody against eGFP and protein E. Cells 
were transfected with the respective constructs and protein expression was monitored 24 
hours post-transfection. Due the secondary antibodies cells expressing eGFP appear in green 
(FITC) and cells expressing protein E in red (rodhamine red). After 3 days post transfection 
supernatant was harvested and used to transfect fresh cells. Again, cells were stained 24 hours 
post infection. 
 
Figure 5. A. Quantitative PCR of intracellular RNA of cells transfected with viral RNA as 
indicated. Primers and probes bound to sequences coding for the capsid protein which 
excluded the detection of replicon ΔC. B. Quantitative PCR of intracellular RNA of cells 
transfected with viral RNA as indicated. Primers and probes bound to sequences coding for 
domain III of protein E which excluded the detection of all mutant RNAs except replicon ΔC. 
C. Quantitative PCR of RNA in the supernatant of cells transfected with viral RNAs as 
indicated. Primer and probes as in A. D. Quantitative PCR of RNA in the supernatant of cells 
transfected with viral RNAs as indicated. Primer and probes as in B.  
 
Figure 6. Export efficiencies of replicon ΔC calculated by the percentage of extra 
cellularRNA in relation to intra-cellular RNA. 
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Helices 2 and 3 of West Nile Virus Capsid Protein Are Dispensable
for Assembly of Infectious Virions
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The internal hydrophobic sequence within the flaviviral capsid protein (protein C) plays an important role
in the assembly of infectious virions. Here, this sequence was analyzed in a West Nile virus lineage I isolate
(crow V76/1). An infectious cDNA clone was constructed and used to introduce deletions into the internal
hydrophobic domain which comprises helix 2 and part of the loop intervening helices 2 and 3. In total, nine
capsid deletion mutants (4 to 14 amino acids long) were constructed and tested for virus viability. Some of the
short deletions did not significantly affect growth in cell culture, whereas larger deletions removing almost the
entire hydrophobic region significantly impaired viral growth. Efficient growth of the majority of mutants
could, however, be restored by the acquisition of second-site mutations. In most cases, these resuscitating
mutations were point mutations within protein C changing individual amino acids into more hydrophobic
residues, reminiscent of what had been observed previously for another flavivirus, tick-borne encephalitis
virus. However, we also identified viable spontaneous pseudorevertants with more than one-third of the capsid
protein removed, i.e., 36 or 37 of a total of 105 residues, including all of helix 3 and a hydrophilic segment
connecting 3 and 4. These large deletions are predicted to induce formation of large, predominantly
hydrophobic fusion helices which may substitute for the loss of the internal hydrophobic domain, underlining
the unrivaled structural and functional flexibility of protein C.
The genus Flavivirus within the family Flaviviridae comprises
important human pathogens such as Japanese encephalitis vi-
rus (JEV), the dengue viruses (DENV), yellow fever virus
(YFV), tick-borne encephalitis virus (TBEV) and West Nile
virus (WNV) (28). The 50-nm flavivirus virion is composed
of two surface proteins, envelope (E) and membrane (M, de-
rived from its precursor protein prM by furin-mediated cleav-
age), and the nucleocapsid consisting of the capsid protein
(protein C) and the 11-kb positive-stranded RNA genome. In
addition to the three structural proteins C, prM, and E, the
genome encodes seven nonstructural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, and NS5), which are necessary for
replication of the RNA genome (28). Structural and nonstruc-
tural proteins are derived from a single polyprotein, which is
co- and posttranslationally processed into mature proteins by
viral and cellular proteases (6, 28).
The assembly of the virions is thought to occur at the mem-
brane of the rough endoplasmic reticulum (ER) (28, 32). Pro-
tein C, which is the protein located at the very N terminus of
the polyprotein, facilitates translocation of the subsequent pro-
tein prM into the lumen of the ER via an internal signal
sequence located at its C terminus. Proteins prM and E remain
attached to the host-derived membrane by spanning the lipid
bilayer twice via their C-terminal anchor regions (38, 47, 48).
Protein C is originally also anchored to the ER membrane via
the C-terminal internal signal sequence. However, this signal
sequence is cleaved off by the viral NS2B/3 protease, thereby
producing the mature, cytoplasmic form of the protein (4, 30,
40). Multiple copies of protein C and one copy of the RNA
genome form the nucleocapsid. In the virion, the nucleocapsid
appears not to directly interact with the surrounding mem-
brane and the embedded surface proteins prM and E (47) and
furthermore lacks, in contrast to the icosahedrally arranged
surface proteins, a well-ordered structure (25, 49). Instead, the
nucleocapsid may nonspecifically interact with the ER mem-
brane during budding by virtue of a hydrophobic, mostly heli-
cal sequence element which is present at a conserved position
in all of the flavivirus protein C sequences (31, 35).
The recently solved three-dimensional (3D) structures of the
DENV-2 and Kunjin virus C proteins (Kunjin virus is an Aus-
tralian strain of WNV) (11, 31) support this notion. The nu-
clear magnetic resonance 3D structure of DENV-2 protein C
indicates that the protein, composed of four  helices, forms a
dimer in solution (31). The contact surfaces for dimerization
are provided by helices 2 and 4. Helix 2 comprises most of
the internal hydrophobic sequence within protein C. After
dimerization, the interacting helices 2 form the bottom of a
hydrophobic cleft. The highest density of positively charged
residues is found on the opposite side of the dimer, on the
surfaces of helices 4, which interact by forming a coiled coil.
Accordingly, a model suggesting that the hydrophobic cleft
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presumably enables the nucleocapsid to attach to the mem-
brane and that helices 4 play a potential role in interaction
with the negatively charged RNA genome has been established
(31).
The functional importance of the conserved internal hydro-
phobic domain in virus assembly and/or dimerization of pro-
tein C is supported by studies with a variety of flaviviruses. For
instance, removal of major parts of this sequence element in
TBEV resulted in an increased formation of capsidless subviral
particles (19), the secretion of which is also observed in the
course of natural infection or by expression of proteins prM
and E only (1, 22–24, 36). Large deletions were tolerated only
upon the acquisition of additional mutations increasing the
hydrophobicity of the protein (21). These results are in good
accordance with studies of YFV protein C (42) and WNV, in
which case removal of the entire helix 2 produced a nonin-
fectious phenotype (44). Furthermore, in DENV, removing
large parts of the hydrophobic domain abolished both the
ability to dimerize in vitro (46) and the ability to associate with
the ER membrane (35). Taken together, these studies under-
lined the important roles of the conserved internal hydropho-
bic sequence in dimerization of protein C and virion assembly.
In the present study, we set out to systematically test the
functional role of the hydrophobic sequence of WNV protein
C for viral infectivity by introducing deletions ranging from 4 to
14 amino acids. Some of the smaller deletions were well tol-
erated, whereas growth with others was, consistent with previ-
ous findings with TBEV (21), dependent on the acquisition of
second-site point mutations. Surprisingly, two well-replicating
pseudorevertants were shown to have restored growth capabil-
ity through spontaneously enlarged deletions. These mutants
lacked more than one-third of the protein C sequence. The
spontaneously deleted sequences included all of helix 3 and a
hydrophilic loop connecting helices 3 and 4. Our data pro-
vide evidence that although removal of large parts or the entire
internal hydrophobic domain usually causes severe defects in
viral growth, truncating protein C even further can largely
revert this impairment. A viable WNV mutant with capsid
proteins less than two-thirds of the size of the natural protein
was generated by reverse genetics, and its growth properties
were analyzed in comparison to those of the wild-type virus.
Secondary-structure predictions suggest that in these mutants,
the formation of large, hydrophobic fusion helices might com-
pensate for the loss of the conserved hydrophobic domain.
MATERIALS AND METHODS
Cells and virus. Vero (ATCC CCL-81) cells were grown in Eagles minimal
essential medium (EMEM) supplemented with 10% fetal bovine serum (FBS;
PAA Laboratories), 1.5% glutamine (200 mM; Cambrex), 1% penicillin-strep-
tomycin (10,000 U/ml penicillin and 10 mg/ml streptomycin; Sigma), and 15 mM
HEPES, pH 7.4. Infections were performed in the presence of 2% instead of
10% FBS, and after infection, cells were maintained in medium lacking FBS. For
virus stock production, FBS was replaced with 1% (wt/vol) bovine serum albumin
(BSA). BHK-21 cells used for introduction of in vitro-transcribed RNA were
handled in growth medium (EMEM supplemented with 5% FBS, 1% glutamine,
0.5% [10 mg/ml] neomycin, and 15 mM HEPES, pH 7.4) and maintenance
medium (EMEM supplemented with 1% FBS, 1% glutamine, 0.5% neomycin,
and 15 mM HEPES, pH 7.4) as described earlier (19, 33, 41).
The WNV strain used in this study was originally isolated from a dead crow
collected during the summer of 1999 in New York City (crow V76/1). The virus
was passaged three times in Vero cells and once in suckling mouse brain prior to
the construction of the infectious cDNA clone.
Cloning procedures. The two partial cDNA clones pWNV-K1 and pWNV-K4
were constructed as described in previous studies (7, 33, 45), with the exception
that pBR322 (5) had been modified by replacing the tetracycline resistance gene
with a multiple-cloning site (BspEI-SwaI-PacI-NotI-SwaI-AatII). For the intro-
duction of deletions into the capsid protein within plasmid pWNV-K1, the Gene
Tailor site-directed mutagenesis system (Invitrogen) was used. Detailed primer
sequences for all constructs are available from the authors upon request.
All constructs were amplified in Escherichia coli strain DH5 cells and char-
acterized by complete sequencing of both strands of the entire inserts.
In vitro RNA transcription and transfection. In vitro transcription with T7
RNA polymerase (Ambion T7 Megascript transcription kit) and transfection of
BHK-21 cells by electroporation were performed as described in previous studies
(12, 19). In the case of transcription reactions required as standards in real-time
PCR analysis, the pWNV-K1 template DNA was degraded by incubation with
DNase I for 15 min at 37°C, and the RNA was purified and separated from
unincorporated nucleotides by using an RNeasy Mini kit (Qiagen). RNA con-
centrations were estimated from band intensities or, for determination of the
RNA standard concentration, measured spectrophotometrically.
Immunofluorescence staining. Intracellular expression of WNV specific pro-
teins was determined by indirect immunofluorescence staining of the envelope
protein E. Accordingly, RNA-transfected BHK-21 cells were seeded into 24-well
plates and supplied with growth medium (EMEM with supplements and 5%
FBS), which was exchanged for maintenance medium (EMEM with supplements
and 1% FBS) at 20 h posttransfection. After 24 or 48 h, cells were treated with
1:1 acetone-methanol for fixation and permeabilization. To specifically detect
WNV protein E, a cross-reactive polyclonal antibody directed against JEV pro-
tein E was used (dilution, 1:50). Staining was performed with a secondary fluo-
rescein isothiocyanate-conjugated anti-rabbit antibody (Jackson Immuno-
Research Laboratories) as suggested by the manufacturer.
Hemagglutination assay (HA). For the detection of WNV viral and/or subviral
particles in supernatants of infected cells, a rapid assay based on the agglutina-
tion of erythrocytes, which is induced by the interaction with viral particles, was
applied (8, 13). Briefly, virus supernatants were diluted 1:1 in borate-buffered
saline (120 mM sodium chloride, 50 mM sodium borate, pH 9.0) containing 0.4%
BSA for particle stabilization. Subsequently, this mixture was further diluted to
produce a geometrical dilution row. Fifty microliters of each of the diluted
samples was mixed with the same amount of a 0.5% solution of goose erythro-
cytes in round-bottom 96-well plates and incubated for 3 h at room temperature.
Virus-induced agglutination of erythrocytes was visible by the lack of sedimented
erythrocytes; the examination of plates was performed by visual inspection.
Mutant stability. To assay the genetic stability of transfected mutants, super-
natants of transfected cells were diluted until the end point of infectivity was
reached. The supernatant corresponding to the end point was then transferred
onto fresh cells, and these passages were repeated at least twice. Subsequently,
RNA was isolated and sequence analysis was performed by using the cDNA
synthesis system of Roche Applied Science and standard PCR and sequencing
protocols.
RNA replication and export. Intracellular RNA replication was monitored by
real-time PCR as described previously (20, 41) with minor modifications. Briefly,
Vero cells grown in six-well plates were incubated with wild-type and mutant
WNV stock preparations at a multiplicity of infection (MOI) of 1. After 1 h, the
cell monolayer was washed and supplied with growth medium which contained
1% BSA and 15 mM HEPES instead of FBS. At selected time points, cells were
detached by trypsin incubation and washed twice in phosphate-buffered saline
(PBS) (pH 7.4) containing 1% BSA. Cytoplasmic RNA was purified from these
cells (RNeasy Mini kit; Qiagen) and was subjected to real-time PCR (PE Applied
Biosystems) quantification as described previously (20, 41). The primers (5-TC
AGCGATCTCTCCACCAAAG-3 and 5-GGGTCAGCACGTTTGTCATTG-
3) and probe (5-Fam-TGCCCGACCATGGGAGAAGCT-Tamra-3) targeted
a region within the envelope gene of the WNV genomic RNA. RNA equivalents
were finally determined from a standard curve based on an RNA preparation of
known concentration which was serially diluted in cell lysates of negative control
cells and purified according to the same protocol.
The RNA content in supernatants of transfected cells was measured as pub-
lished recently (41). Accordingly, prior to quantification by real-time PCR, ali-
quots of supernatants were cleared by low-speed centrifugation and RNA was
purified by using the QIAamp viral RNA Mini kit (Qiagen) as suggested by the
manufacturer. RNA export was finally calculated by determining the percentage
of total RNA (intracellular and extracellular) in the supernatant fraction.
Cytotoxicity assay. Similar to the RNA replication and export experiments,
Vero cells were seeded into six-well plates and infected with WNV stock prep-
arations at an MOI of 1, but the growth medium did not contain BSA. Aliquots
of supernatants were transferred into 96-well plates, and cytotoxicity was as-
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sessed by measuring the release of lactate dehydrogenase (LDH) using the
CytoTox 96 nonradioactive cytotoxicity assay (Promega) according to the man-
ufacturers instructions.
Plaque morphology and immunocytochemistry. Vero cells were grown to 80%
confluence in 12-well plates and incubated for 1 h with virus suspensions serially
diluted in infection medium. The cells were subsequently overlaid with EMEM
containing 5% FBS (PAA Laboratories), 1.5% glutamine (200 mM; Cambrex),
1% penicillin-streptomycin (10,000 U/ml penicillin and 10 mg/ml streptomycin;
Sigma), 15 mM HEPES, and 0.25% agarose (Sigma). The plaque morphology
was determined following an incubation period ranging from 6 to 9 days postin-
fection. Accordingly, cells were fixed and stained with a solution containing 4%
formaldehyde and 0.1% crystal violet.
Focus-forming units (FFU) were determined by immunocytochemistry. After
incubation for 6 days, the agarose overlay was removed and cells were fixed with
1:1 acetone-methanol. The cells were rehydrated with PBS (pH 7.4) containing
5% sheep serum for 30 min at room temperature. Subsequently, the cells were
incubated for 1 h at 37°C with a WNV-specific polyclonal antiserum (gamma-
WN/KIS/2) diluted 1:3,000 in PBS (pH 7.4) with 0.2% Tween and 3% sheep
serum. Cells were washed twice with PBS (pH 7.4) containing 0.2% Tween and
3% sheep serum and once with TBS buffer (137 mM sodium chloride, 3 mM
potassium chloride, 25 mM Tris, pH 8.0) containing 0.2% Tween and 3% sheep
serum. The incubation with a 1:400 dilution of an anti-rabbit alkaline phos-
phatase-conjugated secondary antibody was performed in TBS buffer with 0.2%
Tween and 3% sheep serum for 45 min at room temperature. Following two
washes with the same buffer, WNV-specific foci were detected by incubating with
Sigma Fast Red TR/naphthol AS-MX for 10 min.
Computer-assisted sequence analysis. Secondary-structure predictions were
performed using PsiPred (15). Hydrophobicity plots were generated according to
the algorithm of Kyte and Doolittle (26) using PROTEAN (DNASTAR, Inc.)
and a window size of 11.
Nucleotide sequence accession number. The sequence of the WNV isolate
(crow 76/1) was deposited under GenBank accession no. FJ151394.
RESULTS
Establishment of a two-component infectious cDNA clone
for WNV isolate V76/1. To generate a tool for WNV reverse
genetics, the genome of a previously uncharacterized lineage I
isolate (see Materials and Methods) (Table 1) was reverse
transcribed, sequenced, and assembled into two plasmids from
which, after in vitro ligation, full-length genomic RNA could
be transcribed (Fig. 1A). To verify the functionality of the
infectious cDNA clone, full-length RNAs were transcribed in
several independent experiments and introduced into BHK-21
cells by electroporation. An apparent cytopathic effect (CPE)
was observed in cells at day 2 posttransfection, indicating virus
replication. The supernatants of transfected BHK-21 cells were
harvested and used to inoculate Vero cells, which are more
susceptible to infection by WNV than BHK-21 cells (unpub-
lished observation). At day 2 postinoculation, the release of
infectious virions into the supernatant was tested by plaque
assays on fresh Vero cells, indicating that virus had grown to
high titers of typically 5  108 PFU/ml. Thus, the growth
properties of the recombinant virus were virtually indistin-
guishable from those of the parental wild-type virus, which was
furthermore confirmed by repeated growth curve analyses
(data not shown).
Deletions within helix 2 of WNV protein impair viral
growth to various degrees. To better characterize the func-
tional importance of the hydrophobic helix 2 in WNV protein
C, a set of nine deletions (Fig. 1B) was introduced into the
infectious cDNA clone. Genomic RNAs were transcribed in
vitro and used to transfect BHK-21 cells. Intracellular protein
E expression was determined by immunofluorescence staining,
using wild-type RNA and untransfected cells as positive and
negative controls, respectively. At 24 h posttransfection, all of
the samples presented a very similar picture, with approxi-
mately 10% of the cells being stained by immunofluorescence
(data not shown). At 48 h posttransfection, the number of
positive cells, however, had increased to 100% for deletion
mutants 4/1, 4/3, and 4/4, thus being indistinguishable
from wild-type-RNA-transfected cells (Fig. 2A). In contrast,
cell culture spreading was reduced in all other mutants, with
the most significant effect observed for mutants 7/2, 10, and
FIG. 1. Capsid deletion mutants of WNV. (A) Schematic drawing
of the two partial WNV cDNA clones (not to scale). The WNV
genome was engineered as two partial cDNA clones into pBR322 using
5 PacI and 3 NotI restriction sites. pWNV-K1 contains the T7 pro-
moter sequence (open arrow) and bp 1 to 3339 of the WNV genomic
sequence. The second plasmid, pWNV-K4, contains the sequence cor-
responding to WNV bp 3282 to 11029 and the hepatitis  virus ri-
bozyme sequence (HDVr). To generate full-length DNA templates for
in vitro transcription, the two clones are ligated in vitro subsequent to
cleavage at the BstEII site at nucleotide position 3321/3326. In vitro
transcription is driven by the T7 promoter, and the HDVr sequence
ensures the production of an authentic 3 end. (B) Schematic drawing
of the positions and sizes of the engineered deletions. Deletions of 4,
7, 10, or 14 amino acids (aa) were introduced into helix 2 of WNV
protein C as indicated by the broken arrows. The respective amino acid
positions are indicated, as well as the nomenclature used for mutants
throughout the study. NCR, noncoding region.
TABLE 1. WNV V76/1 isolate-specific genomic
sequence differences
Nucleotide
no.a
Nucleotide in:
Amino acid
difference Location
NY99-
flamingo382-99
(GenBank accession
no. AF196835)b
WNV V76/1
(GenBank
accession no.
FJ151394)
1118 C U A3 V E
1285 C U Silent E
3138 U C Silent NS1
6735 C A Silent NS4A
7015 U C Silent NS4B
7491 G U Silent NS4B
8811 U C Silent NS5
10851 A G NAc 3 noncoding
region
a Genome position numbers are the same for both isolates.
b The genomic sequence of the isolate used for sequence comparison
(GenBank accession no. AF196835) is published in reference 27.
c NA, not applicable.
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14 (Fig. 2A). Notably, deletions 4/2 and 7/2 exhibited a
more distinct defect than the other deletions of the same
length. Sequence inspection (Fig. 1B) indicates that both of
these deletions are located within the most hydrophobic sec-
tion of the helix (LALL-AFF) suggesting that the loss of hy-
drophobicity even more than the length of the deletion may
cause the observed defect in cell culture spreading.
To further evaluate the production of infectious virions and
to assess the export of viral particles by the infected cells, we
inoculated a monolayer of fresh Vero cells with supernatants
of transfected cells. At day 6 postinoculation, virus particles in
supernatants were quantified by HAs (Fig. 2B). Cells infected
with mutants 4/1, 4/3, and 4/4 were capable of exporting
viral particles as much as wild-type virus. In comparison, mu-
tants 4/2, 7/1, 7/3, and 10 exhibited some degree of im-
pairment, whereas mutants 7/2 and 14 were found to be
incapable of producing infectious particles under these exper-
imental conditions. Whereas these data mostly correlated well
with the above-described immunofluorescence results, there
are also discrepancies (such as with mutant 4/2, which pro-
duced more HA-reactive particles than one would have ex-
pected from the immunofluorescence data). This can be ex-
plained by the selection of pseudorevertants already in this first
passage, a phenomenon which is analyzed in detail in a later
section.
The supernatants tested in HA were also subjected to plaque
and focus formation assays to quantify the infectious titers of
the various mutants. However, only wild-type virus, but none of
the mutants, formed visible plaques on Vero cells at 6 days
postinfection. Infectious titers obtained by focus assay
amounted to 1  106 FFU/ml for mutants 4/4 and 7/3, 5 
105 FFU/ml for mutants 4/1 and 4/3, and 1  105 FFU/ml
for mutants 4/2, 7/1, and 10, whereas no infectious parti-
cles were detected for mutants 7/2 and 14, in good agree-
ment with the above-described HA data. Thus, the titers for all
mutants were significantly lower than that obtained for wild-
type virus (5 108 FFU/ml), suggesting that a large percentage
of the particles produced by these mutants (as detected by HA)
were not infectious or did not initiate the formation of visible
foci.
FIG. 2. Infectious properties of WNV protein C deletion mutants. (A) Viral spread in cell culture. BHK-21 cells were transfected with wild-type
(wt) or mutant in vitro-transcribed RNAs as indicated. As a control, mock-transfected cells were used. at 48 h posttransfection, intracellular protein
E expression was visualized by immunofluorescence staining using a polyclonal antibody directed against JEV protein E which is cross-reactive to
WNV protein E. As secondary antibody, an anti-rabbit fluorescein isothiocyanate conjugate was used. (B) Cell culture passage. Supernatants of
transfected cells were used to inoculate fresh Vero cells. At 6 days postinoculation, the release of virus particles was assessed by subjecting aliquots
of the supernatants to HA. Twofold serial dilutions of supernatants were tested, and the titers (indicated on the left) are expressed on a log2 scale
(samples were measured in duplicate). Error bars indicate standard deviations.
5584 SCHLICK ET AL. J. VIROL.
 o
n
 June 2, 2009 
Bibliothek der M
edUniW
ien (78085)
 at 
jvi.asm.org
D
ow
nloaded from
 
Spontaneous mutations are selected during cell culture pas-
sages. In order to test whether some of the WNV protein C
mutants might revert to a better growth phenotype, end point
dilution passages on Vero cells were performed and viral titers
were monitored. Improved growth properties were indeed ob-
served for mutants 4/2, 7/1, 7/2, 7/3, and 10 at different
passage numbers, whereas several rounds of blind passaging of
mutant 14 failed to produce a viable revertant. To investigate
if these changes in phenotype were a direct result of additional
alterations within the protein C sequence, viral RNA was iso-
lated from supernatants of infected cells and subjected to re-
verse transcription-PCR and sequence analysis. Notably, se-
quencing of the protein C-coding region indeed verified the
appearance of second-site mutations (Table 2). In most of the
cases, and consistent with previous findings obtained with
TBEV (21), point mutations that represented amino acid
changes to more hydrophobic residues had evolved; however,
most of these amino acid changes were, in contrast to findings
with TBEV, located upstream of the original deletion (Fig.
3A). In total, five different point mutations were identified,
with one of the point mutations, P22L, appearing more fre-
quently than others and in the sequence context of two differ-
ent engineered deletions.
Furthermore, and much to our surprise, we also identified
mutations in which the original deletions were enlarged to
lengths of 36 and 37 residues, respectively (Fig. 3B). Passaging
of mutants 10 and 7/3 resulted in the appearance of large
deletions removing more than one-third of the entire amino
acid sequence of protein C. Mutant 10 evolved into a deletion
of residues G40 to Q75 (termed 36) and furthermore con-
tains a conservative D-to-E exchange at the deletion border
(position 39). This deletion removed all residues of helices 2
and 3 as well as flanking residues, thus producing a capsid
protein lacking the entire internal hydrophobic sequence (31).
The second large deletion mutant (termed 37) originated
from mutant 7/3 and had residues L51 to E87 and thus part
of helix 2, all of helix 3, and part of helix 4 removed. This
mutant was predominant in the sequence pattern obtained
after two cell culture passages (Table 2). However, apparently
another pseudorevertant, which contained the original 7/3 de-
letion in combination with a single point mutation, R45L,
arose in the same passaging experiment and outgrew the large
deletion mutant during subsequent passages (Table 2, passage
5). A similar phenomenon was observed with mutant 7/2, in
which case the original P22L mutation was replaced by a K31M
mutation at later passages. In contrast, the same P22L muta-
tion was also observed to arise in mutant 7/1 but there was
complemented by a second amino acid change (M34L) at a
later passage. These observations illustrate the competition of
pseudorevertants with presumably variable evolutionary fitness
during these cell culture passages.
Recombinant mutants 36 and 37 can be readily passaged
in cell culture. The unexpected tolerance of protein C toward
deletions comprising 36 and 37 amino acids encouraged us to
investigate these mutations in more detail. To ensure that the
observed phenotypes were indeed a direct consequence of the
identified alterations, the 36 and 37 deletions were engi-
neered into the WNV wild-type backbone using the infectious
cDNA clone. Immunofluorescence staining at 48 h posttrans-
fection of in vitro-transcribed RNA (Fig. 3C) suggested that
mutants 36 and 37 were indeed viable.
To further characterize the growth of these mutants, plaque
and focus assays were performed on Vero cells. Even after
incubation for 6 days, no plaques could be identified for both
mutants, whereas wild-type plaques reached a size of between
8 and 15 mm (12.6  2.4 mm) (Table 3). In contrast, both
mutants were capable of forming foci on Vero cells, thus con-
firming their infectivity. These were, however, at least four
times smaller than wild-type foci, indicating their reduced abil-
ity to spread in cell culture (Table 3). Nevertheless, both mu-
tants achieved significantly higher titers (1  107 FFU/ml) than
their respective parental mutants 10 (1 105 FFU/ml) and 7/3
(1  106 FFU/ml), thus confirming the notion that extension of
the original deletions to 36 and 37 amino acids within protein C
indeed caused improved cell culture growth properties.
Subsequently, we tested whether mutants 36 and 37 could
be serially passaged in Vero cells and if that would provoke
additional genetic alterations. A single passage using undiluted
supernatant and three subsequent end point passages were
performed, followed by sequence analysis of the entire ge-
nomes. No further sequence alterations were identified after
the passages. These data indicated that the large deletion mu-
tations present in mutants 36 and 37 are sufficient for pro-
viding efficient growth properties in cell culture and remain
genetically stable.
TABLE 2. Spontaneous mutations as determined by sequence analysis
Mutantb
Mutation(s) at passagea:
1 2 5 8 11
4/1 None None NDc ND ND
4/2 P61L P61L ND ND ND
4/3 None None ND ND ND
4/4 None None ND ND ND
7/1 P22L P22L P22L/M34L P22L/M34L ND
7/2 NDc NDc P22L K31M K31M
7/3 None  L51-E87 R45L R45L ND
10 D39E/G40-Q75 D39E/G40-Q75 D39E/G40-Q75 D39E/G40-Q75 ND
a For the first two passages, concentrated samples were used. Subsequently, supernatants were diluted until the end point of infectivity was reached, and these samples
were subjected to further end point passages.
b The 4-amino-acid deletion mutants were passaged only twice.
c ND, not done (sequence analysis was not performed).
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A combined deletion mutant (48) is severely impaired and
genetically unstable. The deletions present in mutants 36 and
37 affect overlapping but different regions of protein C. We
wanted to investigate whether removal of the entire region
extending from the 5 border of the 36 deletion to the 3
border of the 37 deletion would still yield a viable phenotype.
To this end, mutant 48, including the D39E mutation and
lacking residues G40 to E87 (Fig. 3B), was constructed and
analyzed. Immunofluorescence analysis indicated a strongly
impaired phenotype of mutant 48 (Fig. 3C), and no plaque or
focus formation was observed with this mutant (not shown).
However, a single blind passage was sufficient to rescue a
viable phenotype in Vero cells. Sequence analysis after subse-
quent end point passages revealed a duplication of the residues
flanking the 48-amino-acid deletion (i.e., DuM16-D39EL88-
A94), but the growth properties of this pseudorevertant re-
mained restricted, achieving a titer of only 104 FFU/ml.
RNA export and specific infectivity of mutants 36 and 37
are moderately reduced compared to those of wild-type WNV.
To characterize in detail the capacity of mutants 36 and 37
to replicate, export, and infect, quantitative tests were per-
formed in comparison to wild-type virus. As shown in Fig. 4A,
intracellular RNA replication of both mutants was similar to
that of the wild type at 24 and 48 h postinfection. At 72 and
96 h postinfection, intracellular RNA values of mutant 37
were still at wild-type levels, whereas those of mutant 36
decreased. This decrease was accompanied by strong CPE,
causing a strong reduction of cell numbers at these time points.
FIG. 3. Spontaneous mutations in the WNV capsid protein. (A) Second-site point mutations identified after passaging in Vero cells. The point
mutations were identified at the indicated amino acid positions (marked on top) within a region corresponding to helix 1 (open box), helix 2
(gray box), and surrounding residues. The originally engineered deletions are shown by arrows, and the second-site point mutations are marked
in bold and underlined. On the right, the corresponding nucleotide exchanges are listed. (B) Large deletions 36 and 37, identified after passaging
of mutants 10 and 7/3, respectively. The helical parts of the capsid protein are indicated by boxes, and helix 2 is highlighted in gray. The
positions of the large deletions are indicated by arrows. Furthermore, an artificial large deletion mutant (i.e., 48) was constructed, lacking all
residues which had been spontaneously deleted in both 36 and 37. The precise nucleotide deletions are shown on the right. (C) Immunoflu-
orescence analysis of large deletion mutants. The large deletions (i.e., 36, 37, and 48) were engineered into the infectious cDNA clone, and
mutants were tested as described for Fig. 2A.
TABLE 3. Growth properties of mutants 36 and 37
Virus
mm (mean  SD)
Titer (FFU/ml)
Plaque sizea Focus sizeb
Wild type 12.6  2.4 19.8  2.86 5  108
36 2.85  0.63 1  107
37 5.05  1.07 1  107
a Mean plaque size was determined at day 6 postinfection. None of the capsid
deletion mutants induced plaque formation, even when incubation was pro-
longed to 9 days postinfection.
b Mean focus size was determined at day 6 postinfection.
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To confirm the visually observed CPE, cytotoxicity was quan-
titatively assessed by measuring the release of LDH into the
supernatants of infected cells. As shown in Fig. 4E, LDH
release from cells infected with mutant 36 was in the same
range as for the wild type and mutant 37 until 48 h postin-
fection. In contrast, at the later time points, LDH levels in
supernatants of 36-infected cells were significantly higher
than others thus confirming its high cytotoxicity and suggesting
that the decreased intracellular RNA values for 36 at 72 and
96 h postinfection were indeed a consequence of excessive cell
deaths (compare Fig. 4A and E).
Quantification of RNA release into the supernatants re-
vealed moderate differences between protein C deletion mu-
tants and wild-type virus. Mutants 36 and, particularly, 37
released less viral RNA into the supernatant than the wild type
at 24 h postinfection (Fig. 4B). Mutant 37 achieved wild-type
levels at later time points; however, 36 remained approxi-
mately one order of magnitude below the wild-type control at
FIG. 4. Characterization of mutants 36 and 37. Approximately 106 Vero cells were infected at an MOI of 1 with the indicated virus
preparation. Wild-type virus and infection medium were used as the respective positive and negative controls. (A) RNA replication (intracellular
RNA) was measured by real-time PCR at the indicated time points. (B) The RNA export kinetics (RNA in supernatant) of mutants 36 and 37
was monitored by real-time PCR. (C) The percentage of exported relative to total RNA (intra- plus extracellular RNA) was calculated for the 48-h
time point. (D) Release of viral particles into the supernatant was assessed by HA. (E) Cytotoxicity was assessed by CytoTox 96 nonradioactive
cytotoxicity assay (Promega) using supernatants of the same samples. The respective optical density at 490 nm (OD490) values, representing LDH
release of disintegrating cells, are shown. (F) Specific infectivity of mutants 36 and 37 and wild-type virus. The specific infectivity was calculated
by determining the ratio of RNA (real-time PCR) to infectious units (focus assay) in virus stock preparations. Mean values from two independent
experiments with error bars indicating standard deviations are shown. wt, wild-type.
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all times. The decreasing values after 48 h (i.e., at 72 and 96 h)
presumably reflect the loss of producing cells caused by the
mutant’s prominent cytotoxicity, thus calling into question the
accuracy of the quantitative data at the later time points. To
better compare the export efficiencies of mutant and wild-type
RNAs, the percentage of total (extracellular and intracellular)
RNA equivalents in the supernatant was calculated for the
48-h time point, at which time effects of cytotoxicity were still
low and comparable among the samples. As illustrated in Fig.
4C, export efficiencies of mutants 36 and 37 were about
two-thirds and half of the wild-type value, indicating that the
mutated capsid proteins, although clearly less efficient in pack-
aging of RNA and/or assembly of virions, were still able to
facilitate the export of a significant percentage of the total
RNA from infected cells. To further determine the export of
viral particles, the same supernatants as used for the quantifi-
cation of viral RNA were subjected to HA. As shown in Fig.
4D, the results of this analysis were in good agreement with the
RNA data shown in Fig. 4B. For mutant 37, the release of
viral particles was delayed but reached nearly the wild-type
level at the latest time point. In contrast, the level for mutant
36 remained below that of the wild type by approximately 3
log2 dilutions (i.e., approximately 8-fold) at all times, similar to
the approximately 10-fold difference observed in the RNA
values.
To quantitatively compare the specific infectivities of mutant
and wild-type viruses, virus preparations were subjected to
quantitative PCR to determine the number of RNA equiva-
lents (presumed to correlate to the number of virions) and to
focus assays to quantify infectious units in these preparations.
The ratio of RNA equivalents to FFU was then calculated, and
results are plotted in Fig. 4F. Whereas this ratio was approx-
imately 10 for wild-type virus (i.e., 1 out of 10 RNA equiva-
lents/virions caused an infectious focus), it was between 10-
and 100-fold higher in the case of the two deletion mutants,
indicating reduced specific infectivity.
In conclusion, the quantitative comparisons indicated mod-
erate but significant impairments of both viral export and entry
caused by the deletion mutations.
Large deletions are predicted to cause complex rearrange-
ments of the overall helical composition of protein C. Notably,
protein C deletion mutants 36 and 37 are capable of pro-
ducing infectious virions, whereas mutants with deletions of
fewer amino acids are much more severely impaired (i.e., 4/2,
7/1, 7/2, 7/3, and 10) or noninfectious in cell culture (i.e.,
14). To obtain further insight into the structural conse-
quences of deletions 36 and 37, the protein C sequences of
these pseudorevertants were subjected to secondary-structure
prediction analysis (PsiPred) (15) and compared to the wild-
type sequence. In Fig. 5A, the secondary-structure prediction
for the WNV V76/1 sequence is presented, with positions of
helices being almost identical to those defined in the crystal
structure (11). In addition, we determined the Kyte-Doolittle
hydrophobicity profile (26). The spontaneous enlargements of
the deletions apparently removed a hydrophilic region extend-
ing from 3 to the beginning of 4 (Fig. 5A, lower panel). This
suggests that the spontaneous deletions compensate for the
loss of the hydrophobic helical structure as represented by
helix 2 by removing another, more hydrophilic region (Fig.
5A). Subsequently, the sequences of protein C deletion mu-
tants (i.e., 36, and 37) were analyzed. As illustrated in the
WNV crystal structure (11), the spontaneous deletion of 36
amino acids resulted in complete removal of helices 2 and 3
(Fig. 5B, lower panel). The secondary-structure prediction sug-
gested the formation of a large single  helix (Fig. 5B, upper
panel) by fusion of helices 1 and 4. Whether the mutant
protein (i.e., a polypeptide of only 61 amino acids) is likely to
adopt a stable conformation in solution remains elusive, and it
will be interesting to investigate this using recombinant pro-
teins. However, it is certainly conceivable that such a long
fusion helix might form upon insertion of protein C into the
ER membrane. Similarly, the formation of a fusion helix was
predicted in the analysis of the second large deletion mutant
(i.e., 37, illustrated in Fig. 5C). Notably, in the crystal struc-
ture, the remainders of helices 2 and 4 are oriented toward
each other, thus suggesting, albeit not proving, that the forma-
tion of a large fusion helix might indeed be possible.
DISCUSSION
The internal hydrophobic domain of the flaviviral protein C
is a functionally important region involved in protein dimer-
ization and membrane interaction during assembly of the
virion (19, 31, 34, 46). In earlier reports, it had been demon-
strated that mutants lacking the entire internal hydrophobic
sequence of protein C are either severely impaired or not
viable at all (21, 42, 44). Although this was also observed with
some of the WNV deletion mutants analyzed in this study, the
pseudorevertant 36, lacking amino acids G40 to Q75 and thus
the entire conserved hydrophobic domain, surprisingly dem-
onstrates that efficient virion assembly and cell culture growth
are in fact possible even in the complete absence of this region.
37, the second large, spontaneously emerged WNV capsid
deletion mutant, lacks residues L51 to E87 and thus also large
parts of this domain. Both mutants grew well in cell culture,
indicating that highly truncated capsid proteins can be func-
tional.
A remarkable flexibility of protein C toward deletions and
sequence alterations has already been observed in earlier stud-
ies (19, 21, 42, 43, 50). Protein C is essential for binding and
packaging of genomic RNA and contributes to particle assem-
bly and stability (reviewed in reference 38). RNA binding has
been assigned to the highly basic N- and C-terminal parts of
the protein (17). Notably, as tested in a YFV trans-packaging
system, one intact terminus is sufficient for the encapsidation
of genomic RNA (42). Thus, nearly 40 residues of the N ter-
minus of YFV protein C could be removed while the ability to
package RNA was retained. Similarly, 27 residues of its C
terminus, including the entire helix 4, were dispensable for
packaging. Based on their observations with mutants contain-
ing deletions in both termini, Patkar et al. proposed a mech-
anism in which the N terminus is involved in initial binding of
the genomic RNA, followed by binding of the C terminus (42).
The capacity to bind and package viral RNA is largely pre-
served in both mutant 36 and mutant 37 proteins, as mea-
sured by their capacity to export RNA into the supernatants of
infected cells. Another functional requirement of protein C is
to mediate interaction with the ER membrane during budding
(19, 35). It is believed that this interaction involves the hydro-
phobic cleft present on the surface of dimeric protein C (31).
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In the dimer of protein C, helices 2 from each monomer
interact with each other, thus forming the bottom of this cleft.
It is puzzling that mutants 36 and 37 still produced infec-
tious particles even though the entire or large parts of helix 2
were missing. Secondary-structure predictions and hydropho-
bicity plots suggested the formation of new large, hydrophobic
 helices in both of these mutants, whereas a hydrophilic
stretch of residues was lost from both of these proteins. Taken
together, these findings support the idea that the newly formed
fusion helices might functionally substitute for the loss of helix
2. In addition, the protein C dimer serves as the basic building
block in the assembly of the flaviviral nucleocapsid (18). In the
3D structures of flaviviral protein C (11, 31), the dimers re-
semble a three-layer structure with helices 1 on top, helices
2 in the middle, and helices 4 at the bottom. In contrast,
helix 3 is not organized pairwise and seems to serve as a
spacer. Mutant 36 lacks helices 2 and 3 and, as a conse-
quence, the middle part of the three-layer structure is com-
pletely removed whereas the top layer of helices 1 and the
bottom layer of helices 4 remain more or less unaffected (Fig.
5B). Similarly, mutant 37 lacks approximately half of helix 2,
the entire helix 3, and approximately half of helix 4 (Fig.
5C). One might assume that the formation of a fusion helix
(composed of the remainders of helices 2 and 4) results in
the formation of two layers instead of three. Stacking of such
two-layer structures might nevertheless enable multimer for-
mation and nucleocapsid assembly, which has been shown as
an intrinsic property of WNV C and DENV C proteins (11,
31). Therefore, it will be interesting to explore the oligomeric
properties and the atomic structures of the mutant proteins in
future experiments. Mutants 36 and 37, however, had a
significantly reduced specific infectivity and formed only small
foci and no plaques, indicating a significantly attenuated phe-
notype. This attenuation may be caused not only by an assem-
bly defect but also by an impairment during entry and unpack-
aging and/or a reduced physico-chemical stability of the
mutant particles. Indeed, a decreased thermal stability of par-
ticles containing C-terminal deletions [C(77–96)] or deletions
within the internal hydrophobic sequence [C(43–48)] had
recently been observed (42). The impairment of export and,
FIG. 5. Structure predictions for sequences of the wild type (A), deletion mutation 36 (B), and deletion mutation 37 (C). (A) Secondary-
structure prediction and hydrophobicity blot for the WNV V76/1sequence. Residues R23 to R98, which are also present in the Kunjin protein C
crystal structure (11), are shown. The positions of the introduced deletions and the most hydrophilic part of the protein are shown by open boxes.
The spontaneous deletions 36 and 37 are illustrated by black bars below. (B and C) Upper panels, secondary-structure predictions for mutant
protein C sequences and corresponding hydrophobicity blots. Lower panels, deletions on the Kunjin protein C dimer (11). The four helices are
shown, where present, with the same coloring in all three panels (i.e., 1 in green, 2 in blue, 3 in yellow, and 4 in red); the spontaneous large
deletions (i.e., 36 and 37) are shown in gray. All secondary-structure predictions were performed using PsiPred (15), and the hydrophobicity
blots were generated according to the algorithm of Kyte and Doolittle (26). The protein C 3D structure was adapted from the Protein Data Bank
(accession no. 1SFK) using PyMOL software (10). wt, wild-type.
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potentially connected with this observation, an altered cytotox-
icity (i.e., for mutant 36) are likely caused by a partial defect
in particle assembly.
In this study, we also identified spontaneous mutations
which resembled those described previously for TBEV (21),
i.e., exchanges of individual amino acids to more hydrophobic
residues and duplication mutations. In the TBEV study, the
residue changes were, without exception, located downstream
of the originally engineered deletion, whereas this was the case
for only a single mutation in the WNV system. The P61L
mutation in mutant 4/2 resembles a P57L mutation identified
in TBEV mutant C(28–46). Both of these mutations of P to
L are located in the loop between the helix 2 containing the
hydrophobic domain and the subsequent helix 3. All other
WNV second-site point mutations, however, appeared up-
stream of the original deletion and affected residues preceding
or located within helix 1. In addition, the TBEV study (21)
identified two duplications as resuscitating mutations. Simi-
larly, WNV mutant 48 was rescued by the emergence of a
duplication mutation, DuM16-D39EL88-A94, although
growth of the resulting mutant was still highly restricted. Taken
together, these findings suggest that similar mechanisms can
work to compensate for deletion mutations in both TBEV and
WNV and possibly flaviviruses in general.
Flaviviral RNA replication is dependent on the cyclization of
the positive-stranded RNA genome, which is mediated via 5
and 3 cyclization sequences (reviewed in reference 34). In
mosquito-borne flaviviruses, the 5 cyclization sequence is lo-
cated within the amino-terminal coding region of protein C (2,
3, 9, 14, 16, 20, 29, 39). The WNV 5 cyclization sequence
comprises nucleotides 137 to 144, encoding amino acids V14 to
M16 of protein C. In good agreement with the functional
importance of this region, none of the second-site mutations
including also the large deletions affected this part of the
sequence. Thus, intracellular RNA replication should not be
impaired, and indeed, quantitative assessment showed no sig-
nificant differences between mutants 36 and 37 and wild-
type virus.
In conclusion, our data support a functional importance of
the internal hydrophobic domain of the WNV protein C but
demonstrate that this functionality can be substituted for in
dramatically truncated forms of this protein. Deletions of more
than one-third of the protein in the absence of additional
mutations, which would increase hydrophobicity, can generate
functional protein C. As suggested by secondary-structure pre-
dictions for WNV protein C deletion mutants 36 and 37, the
loss of functional elements contained in the hydrophobic helix
2 was presumably compensated for by the formation of hy-
drophobic fusion helices and the extrusion of an intermittent
hydrophilic loop region. The high immunogenicity of mutant
flaviviruses containing deletions within protein C has been
successfully demonstrated (19, 21, 37, 44). Taking into account
the delayed growth kinetics together with the fact that high
titers can be achieved with mutants 36 and 37 in cell culture,
we propose that these large deletion mutants might be partic-
ularly useful vaccine candidates.
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